Ruotong Kang1†
Fushun Kou
Yuan Cheng- 1School of Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China
- 2Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, the First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China
Historically, neutrophils have been regarded primarily as pro-inflammatory cells, yet recent advancements have revealed their phenotypic heterogeneity and functional plasticity with versatile immunophenotypes. Distinct subpopulations of neutrophils exhibit a functional duality, not only initiating and amplifying inflammation, but also actively promoting tissue restoration in diseases, such as inflammatory bowel disease (IBD), colorectal cancer (CRC) and intestinal infections. They contribute to the formation of a dynamic immune microenvironment in concert with the intestinal microbiota, epithelial cells, and other immune cell types. Current first-line therapies for enteric diseases often lack precision in modulating neutrophil functions. In contrast, natural products including alkaloids, polysaccharides, polyphenols, quinones, and glycosides, as well as microbiota-derived metabolites, exhibit distinct advantages for ability to achieve multi-targeted and bidirectional immunomodulation. These compounds target neutrophil activation, migration, neutrophil extracellular trap formation, cytokine release, oxidative stress, and energy metabolism etc. In this review, we systematically examine the heterogeneity and functional diversity of intestinal neutrophils, highlighting their interaction mechanisms with the surrounding microenvironment. Potential of natural products to modulate neutrophil functions via multi-target strategies has not been fully explored. Moreover, the review discusses novel precision therapeutic approaches based on neutrophil nanotechnology and engineered cell drug delivery. These cutting-edge technologies aim to enhance natural products delivery to inflammatory sites, provide controllable regulation of neutrophil function, and facilitate the degradation of pathological structures. Collectively, the study presents new research directions and theoretical frameworks for intervention of natural products in neutrophils of intestinal immune-related disorders, notably IBD and even CRC.
1 Introduction
The intestinal immune system is critical in maintaining systemic homeostasis and protecting against pathogenic invasion. Its dysfunction could lead to the development of various complex immune-mediated intestinal disorders. Multiple immune cell types, including lymphocytes, macrophages, dendritic cells, and neutrophils, coordinate interplay to sustain intestinal immune homeostasis (1). Neutrophils, as the primary effector cells of innate immunity, are a key effector response to tissue infection and inflammation. Recent studies have highlighted their remarkable plasticity and functional heterogeneity within the gut, expanding our understanding of their role beyond innate defense (2). Intestinal neutrophils refer to neutrophils that are recruited from the circulation into the intestinal mucosa in response to homeostatic or inflammatory signals. Shaped by the local microenvironment, particularly the microbiota, they adopt specific functional states. Upon intestinal homeostasis disruption, chemokines and cytokines guide neutrophils into intestinal tissue (3), where they undergo transcriptomic and phenotypic reprogramming into distinct functional subsets (4, 5). Although whether there exist tissue-resident neutrophil populations like macrophages remains controversial, evidence indicates that circulating neutrophils can adapt and persist locally. For instance, subsets such as CXCR4+ neutrophils exhibit transcriptional profiles skewed toward non-immune regulatory roles (6, 7). Further support comes from the phenomenon of “reverse transendothelial migration, “ wherein tissue-reprogrammed neutrophils re-enter circulation (8).
Research has identified distinct functional subsets of intestinal neutrophils. These neutrophil subsets engage in complex interactions with the gut microbiota, epithelial cells, and other immune cells through processes such as migration, phagocytosis, neutrophil extracellular trap formation (NETs) formation, and cytokine production (9, 10). The dynamic equilibrium of neutrophil subset quantity, function, and spatial distribution is a critical determinant of intestinal immune homeostasis. Disruption of this balance can contribute to the pathogenesis and exacerbation of several intestinal immune disorders, particularly inflammatory bowel disease (IBD) and colorectal cancer (CRC) (9).
Current therapeutic approaches for these conditions primarily involve anti-inflammatory agents (such as aminosalicylates), corticosteroids, and biologics (e.g., anti-TNF-α monoclonal antibodies and interleukin inhibitors) (11). The medicinal value of aspirin, a conventional anti-inflammatory medication, in these scenarios has recently been investigated. Current statistical evidence implies that low-dose aspirin (160mg/d) as a supplementary treatment could diminish the likelihood of CRC returning through the PI3K pathway, although its exact modes of action are not yet fully elucidated (12). These treatments aim to control inflammation, alleviate symptoms, and protect the intestinal mucosa by broadly or selectively inhibiting immune activation (13). Still, most of these therapies have notable limitations and side-effects. Specifically, long-term corticosteroid use is associated with severe metabolic and infective complications, whereas biologics are hampered by high cost, variable efficacy, and potential safety risks (14, 15). Furthermore, these therapies tend to modulate neutrophil function in a non-selective manner, which makes it challenging to effectively suppress excessive NETs formation and oxidative burst of pathogenic neutrophils while preserving or enhancing their pathogen-clearance and tissue-repair abilities (16). As a critical element of the immune defense mechanism, NETs have become a major focus for developing direct pharmacological interventions. Notably, PAD4 inhibitors, including GSK484 and Cl-amidine, can block NETs formation by inhibiting histone citrullination (17, 18). Similarly, DNase I degraded the DNA scaffold of existing NETs, and alleviated NETs-mediated immunothrombosis and tissue injury (19). Furthermore, studies indicated that PAD4 inhibitors and DNase I synergistically reduce hepatic metastasis and peritoneal dissemination in CRC models (20). Although the neutrophil elastase inhibitor sivelestat is primarily used for acute lung injury (21), it may theoretically influence NETs formation and require experimental validation in intestinal diseases. Nevertheless, such drugs are often limited by single targets, short half-lives, potential interference with normal anti-infective immunity, and unverified long-term safety (22, 23), precluding their adoption as standard therapies.
Natural products and their derived compounds, encompassing alkaloids, quinones, polysaccharides, polyphenols, glycosides, terpenoids, microbiota-derived metabolites, which offer a promising alternative therapeutic strategy for the bidirectional regulation of neutrophils due to their multi-target mechanisms, low toxicity, and favorable safety profiles (24). These compounds have garnered attention for their potential in bidirectional immune modulation. Numerous studies have demonstrated that natural products can precisely intervene in neutrophil-mediated inflammatory processes and tissue damage (25). Notably, the effects of natural products are not confined to single targets. They also indirectly modulate neutrophil function by influencing epithelial barrier, T-cell differentiation, and the gut microbiota, thereby demonstrating a multi-layered, network-based immunomodulatory potential (26). In addition, emerging strategies point to targeting neutrophils to enhance the therapeutic precision and efficacy of natural products in intestinal immune diseases (27).
Taken together, the review aims to systematically elucidate the heterogeneity and functional diversity of intestinal neutrophils, along with their complex interactions within the intestinal microenvironment. It particularly focuses on how natural products precisely and multi-targetedly modulate neutrophil functions. The objective is to provide a robust theoretical framework and forward-looking insights to guide the development of novel therapeutic strategies that leverage natural products for the precise and bidirectional regulation of neutrophils.
2 Heterogeneity and functional diversity of intestinal neutrophils
2.1 Classification, phenotypic characteristics, and function of intestinal neutrophil subpopulations
Different neutrophil subtypes possess specific surface markers, which serve as key indicators for distinguishing between subtypes. The classification of intestinal neutrophil subpopulations (N1, N2, N3), which is based on their function and activation state, should not be conflated with that of tumor-associated neutrophils (TANs, also termed N1 and N2). In fact, their functional roles are often opposing (Table 1).
Table 1. Classification, phenotypic characteristics and functions of different subtypes of neutrophils in the intestinal tract.
2.2 Dual mechanisms of different neutrophil subtypes in various diseases
Neutrophils play a complex dual role in intestinal diseases and are regulated by specific subtypes. In IBD, neutrophils are recruited to the mucosa in response to inflammatory signals, where they release reactive oxygen species (ROS), proteolytic enzymes, pro-inflammatory cytokines, and NETs. These actions contribute to epithelial barrier breakdown, crypt abscess formation, and amplifying inflammation (3, 40, 41). However, excessive NETs deposition is associated with an increased risk of thrombosis in active IBD, particularly UC, although it may also provide some protective hemostatic functions (42). Furthermore, neutrophils promote the progression of UC colitis and even transform into colitis-associated carcinomas (CAC) through the activation of the JAK/STAT pathway (43, 44). Conversely, specific subsets such as CD177+ neutrophils enhance bactericidal activity and produce tissue-healing factors, thereby supporting mucosal repair (35, 36, 45). Similarly, CXCR4high neutrophils contribute to tissue remodeling via MMP9 secretion (46, 47). In addition, neutrophils produce pro-resolving lipid mediators, vascular endothelial growth factor (VEGF), and MCPIP1, which collectively represent another mechanism to limit excessive inflammation and maintain tissue homeostasis (48).
Within the intestinal tumor microenvironment, the function of neutrophils is influenced by local cytokines and displays context-dependence. In response to stimulation of different cytokines, such as TGF-β, IFN-γ, and IFN-β, neutrophils have the potential to polarize toward an antitumorigenic phenotype (N1) or toward a protumorigenic phenotype (N2) (34, 49–51). N1 neutrophils exert anti-tumor effects through phagocytosis, ROS-mediated cytotoxicity, and recruitment of T cells. N2 neutrophils promote tumor progression by suppressing T cell activity, facilitating angiogenesis via VEGF signaling, and promoting metastasis through MMP9 and NETosis (52, 53). This pro-tumorigenic NETosis can be potently induced by specific members of the dysbiotic intestinal microbiota. A key example is Fusobacterium nucleatum, a pathobiont frequently enriched in CRC. It has been demonstrated to trigger NETs formation, which subsequently enhances tumor cell proliferation and invasiveness, thereby facilitating CRC progression (54). This exemplifies a direct mechanistic link between a dysbiotic bacterium, neutrophil activation, and tumor progression.
Moreover, the functional duality of neutrophils extends to other intestinal disorders. In infectious enteritis, neutrophils provide essential defense against pathogens like Salmonella through phagocytosis, ROS production, and NETs formation (55–57). However, excessive activation can exacerbate tissue damage, as seen in Clostridium difficile infection (58). In irritable bowel syndrome, neutrophils contribute to barrier disruption and chronicity, whereas in intestinal obstruction and necrotizing enterocolitis, their early bactericidal activity may be offset by ROS and protease-mediated injury (59). In diverticulitis, rapid neutrophil recruitment localizes infection and prevents peritonitis, albeit at the cost of local tissue destruction (60–62).
3 Mechanisms of interaction between neutrophils and the microbiome and other cells
Neutrophils are of crucial significance for maintaining intestinal homeostasis and could influence the intestine through three primary interaction mechanisms, including neutrophil-gut microbiota interactions, neutrophil-epithelial cell interactions, and neutrophil-immune cell interactions.
3.1 Neutrophils-gut microbiota
Neutrophils directly or indirectly impact the local gut microbiota via multiple pathways (Figure 1). Their phagocytic activity eliminates pathogens and dysbiotic commensals (63). Activated neutrophils release antimicrobial peptides and ROS via receptors such as GPR120 to eliminate bacteria (38, 57, 64). In addition, NETs can directly capture and kill microorganisms during NETosis (65, 66). Furthermore, NETosis itself can be mediated by the inflammasome, leading to the release of chemokines and cytokines that indirectly affect the microbiota (58, 67). Neutrophils can also activate the NF-κB signaling pathway through TLR receptors and help counteract dysbiosis through the upregulation of AHR-mediated α-defensin 1 (68, 69). Oxidative stress from neutrophils may suppress anaerobes and promote aerotolerant pathogens, worsening dysbiosis (66, 70). This dysbiosis-driven process can exert influence on tumor microenvironments beyond the gut. For instance, a recent single-cell analysis of CRC peritoneal metastasis revealed that intestinal microbiota dysbiosis promotes the recruitment of inflammatory, pro-tumorigenic neutrophils, which in turn drive mesenchymal transition of malignant and mesothelial cells, thereby facilitating metastatic spread (71). This exemplifies a direct link between dysbiosis, neutrophil recruitment, and tumor progression. Conversely, the intestine microbiota precisely regulates neutrophil function through metabolic products and molecular signaling. Specific microbial metabolites influence neutrophil metabolism (72). (Refer to Section 3.8 for details.) The microbiota also employs multiple indirect pathways to fine-tune neutrophil recruitment, activation, and function. These, including the C3 complement pathway (73), AMPK signaling (74), the CXCL3-PD-L1 axis (75), inflammasome activity (76), and Treg cell differentiation (77), form a complex network of immune microenvironment interactions.
Figure 1. The interaction mechanism between neutrophils and gut microbiota, epithelial cells. (A) Neutrophils act on the microbiota through phagocytosis, the release of ROS, antimicrobial peptides (AMPs), and NETs, or through signaling pathways, inflammatory pathways, and immune regulation. Beneficial metabolites in the intestinal microbiota regulate the chemotaxis, apoptosis and NETosis of neutrophils, while pathogen-related molecules strongly activate neutrophils or indirectly regulate them through signaling pathways. (B) Neutrophils and epithelial cells interact through inflammatory pathways, signaling pathways, immune regulation and apoptosis in the four stages of recruitment and adhesion, transepithelial migration, epithelial-site interaction, and repair and regression.
3.2 Neutrophil-epithelial cell
The interaction between neutrophils and intestinal epithelial cells (IECs) can be divided into four key processes. Recruitment and adhesion: Under inflammatory stimuli, IECs release chemokines (78, 79), promoting neutrophil adhesion to and retention within the epithelium via adhesion molecules such as LFA-1/ICAM-1 (80, 81). Transmigration: Neutrophils migrate from the lamina propria to the epithelium guided by IL-8, IL-6, IL-33 (82–84), and other factors, utilizing proteases such as CD11b/CD18 and MMP-9 to cleave tight junction proteins and form migration channels (78, 85). Interaction: Neutrophils interact with IECs at injury sites through NETs release, ROS, degranulation, and pro-inflammatory factors (86, 87). At the same time, IECs modulate neutrophil antimicrobial responses and infiltration levels via the chemerin-CMKLR1/LPO axis (88). Resolution of Inflammation: During resolution, neutrophils undergo apoptosis or release pro-resolving mediators, and thus facilitate tissue repair (89–91). It is noteworthy that excessive neutrophil activity or dysregulated defensins can exacerbate mucosal damage (92).
3.3 Neutrophils-immune cells
3.3.1 Neutrophils-myeloid immune cells
The recruitment of neutrophils is regulated by myeloid immune cells such as monocytes, macrophages, and dendritic cells (DCs). In the pre-inflammatory stage, macrophages and DCs produce factors such as CXCL8 and TNF-α that stimulate neutrophil recruitment (93) (Figure 2). Neutrophils amplify recruitment signals to attract macrophages and DCs, forming a feedback loop. Macrophages also influence neutrophil trafficking in the inflamed mucosa by modulating the endothelial cell (EC) TNFR2 axis (81). When neutrophils and macrophages reach the site of inflammation, they cooperate in phagocytosis and antigen presentation. During the resolution phase of inflammation, macrophages not only drive necroptosis of neutrophils by inhibiting the TLR4/NF-κB pathway (94), but also efficiently clear apoptotic neutrophils through phagocytosis (95). Failed clearance of apoptotic neutrophils leads to secondary necrosis and persistent inflammation. In addition, the metabolic reprogramming cooperation between neutrophils and macrophages can also regulate inflammatory responses (96).
Figure 2. The interaction relationships between neutrophils and myeloid, lymphoid immune cells.Neutrophils act on macrophages, DCs, T cells and B cells through immune regulation, pyroptosis, apoptosis and inflammatory pathways. Myeloid immune cells activate neutrophils in the early stage and phagocytize apoptotic neutrophils in the later stage of inflammation.
3.3.2 Neutrophil-lymphoid immune cells
Neutrophils suppress intestinal inflammation by regulating TCRγδCD8αα-expressing intestinal lymphocyte activation through GSDMD-mediated pyroptosis (35). IL-6 drives Th17 differentiation, and Th17-derived chemokines recruit neutrophils in adaptive immunity (97, 98). In the gut, neutrophils play a crucial role in maintaining the balance between Th17 cells and Treg cells. Meanwhile, lymphocytes also exert feedback regulation on neutrophils (77). Additionally, neutrophils can directly present antigens to T cells under certain conditions (99, 100). In CRC, the interaction between CD15+ neutrophils and CD8+ T cells is linked to tumor progression (101). Neutrophils further support B cell survival, proliferation, and plasma cell differentiation, enhancing IgA production in the mucosa (102).
4 Regulatory effects of natural products targeting intestinal neutrophils
4.1 Alkaloids
Alkaloids are a class of nitrogen-containing organic compounds that occur widely in nature, primarily in plants. These compounds exhibit a range of significant biological activities, including antibacterial, antioxidant, anti-inflammatory, and anti-tumor effects (Figure 3, Table 2).
Figure 3. A schematic overview of natural products regulating intestinal neutrophils is described in detail. These natural products are categorised into nine classes: alkaloids, quinones, polysaccharides, polyphenols, glycosides, terpenoids, microbiota-derived metabolites, natural medicinal materials, and traditional Chinese medicine compounds.The section outside the circle illustrates five common pathways through which natural products intervene in intestinal neutrophils: oxidative stress, pyroptosis, microbiota effects, downstream inflammatory factors influenced by the NF-κB pathway and NETs.
Table 2. Overview of natural products acting in the gut neutrophil.
4.1.1 Berberine
Berberine (BBR) is a natural isoquinoline alkaloid mainly isolated from Berberis aquifolium Pursh, Berberis vulgaris L, and Coptis chinensis Franch (164). BBR inhibited the nuclear translocation of neutrophil elastase (NE) and the subsequent formation of NETs by inhibiting the interaction of linc00668 with NE, which was highly enriched in IECs derived exosomes, thereby effectively regulating the IECs-neutrophil interaction (86). Additionally, BBR reduced intestinal bacteria β-glucuronidase (GUS)-producing bacteria and decreased SN38G conversion to SN38 (the active metabolite of CPT11), thus indirectly reducing neutrophil overactivation and infiltration (103).
4.1.2 Berbamine
Berbamine (BBM), a bisbenzylisoquinoline alkaloid extracted from Chinese herbal medicine Berberis vulgaris L, has been shown to inhibit the formation of NETs after significantly reducing expression of PAD4 in the colon (104). Moreover, BBM attenuated the release of Cit-H3, MPO and NE, which were NETs-associated products (165, 166).
4.1.3 Lycopodium
Lycopodium (LYCO), a member of the Lycopodiaceae family, is enriched in alkaloids and triterpenoids. By restoring the endogenous antioxidants or decreasing the levels of IL-1β and IL-23, LYCO diminished the release of ROS, MPO and free radicals (105, 166). Ultimately, the suppression of ROS inhibited NF-κB signaling and attenuated neutrophil-associated inflammation in the intestinal mucosa (105).
4.1.4 Tetramethylpyrazine
Tetramethylpyrazine, a pyrazine alkaloid derived from the traditional Chinese medicine Chuanxiong, has been demonstrated to reduce neutrophil infiltration in intestinal tissue by decreasing MPO activity and improving intestinal microcirculation (106).
4.1.5 Lemairamin (Wgx-50)
Lemairamin (Wgx-50), a hydroxylamine compound extracted from Sichuan pepper, belongs to the isoquinoline alkaloid class. It inhibited AKT signaling, which could cause reduced expression of pro-inflammatory cytokines, comprising IL-1β, IL-6, CXCL8a, and TNF-α. Then, Wgx-50 directly suppressed neutrophil recruitment to sites of intestinal injury (107).
4.1.6 Cavidine
Cavidine, isolated from Corydalis impatiens, is an isoquinoline alkaloid. Cavidine enhanced the activities of SOD and GSH to reduce the release of ROS. Furthermore, it inhibited the NF-κB signaling pathway, which was involved in the reduced transcription and release of TNF-α and IL-6, thereby mitigating neutrophil-associated inflammation (108).
4.2 Quinones
Quinones are a class of aromatic organic compounds with six carbon atom cyclic diketone structure containing two double bonds in traditional Chinese medicine. According to their chemical structures, they are mainly divided into four types: benzoquinone, naphthoquinone, phenanthraquinone, and anthraquinone. These compounds have significant biological activities, possessing antioxidant, antibacterial, and antitumor properties activities.
4.2.1 Tanshinone IIA
Tanshinone IIA, a phenanthrenequinone compound derived from Salvia miltiorrhiza, attenuated the NF-κB signaling pathway and resulted in a reduction in the transcription and release of pro-inflammatory cytokines, then mitigating neutrophil-associated inflammation and ROS release (109).
4.2.2 Rhein
Rhein, an anthraquinone compound derived from rhubarb. It concurrently reduced the production of pro-inflammatory cytokines and cleaved IL-1β by suppressing NF-κB signaling and the assembly of the NLRP3 inflammasome, ultimately exerting anti-pyroptotic effects and mitigating neutrophil-mediated inflammation (110).
4.3 Polysaccharides
Polysaccharides, large biomolecules formed by the condensation and dehydration of monosaccharide units, are essential carbohydrates with complex molecular structures. It is important to distinguish between pathogen-derived polysaccharides such as LPS, and the plant-derived or fungal-derived polysaccharides discussed herein. LPS, a unique component of Gram-negative bacterial cell walls, is a potent pro-inflammatory molecule. It induces an inflammatory response by stimulating host cells to produce a large number of inflammatory cytokines (167). In contrast, the polysaccharides from medicinal plants or fungi (e.g., Atractylodes macrocephalae, Grifola frondosa) typically exhibit a range of physiological functions, comprising antioxidant, immune-modulatory, anti-infective, etc, thereby exerting protective effects in intestinal inflammation.
4.3.1 Atractylodes macrocephalae Koidz. and Grifola frondosa polysaccharides
Polysaccharide is an effective component of Atractylodes macrocephalae Koidz. (AMP), which is a homologous plant of invigorating spleen and replenishing qi. Grifola frondosa, a medicinal and edible fungus, contains Grifola frondosa polysaccharides (GFPs) as main active components. The polysaccharides from AMP and GFPs directly inhibited neutrophil infiltration, migration and aggregation, together suppressing the levels of inflammatory cytokines in the colonic mucosa (111, 113). Moreover, AMP modulated gut microbiota composition to lower pro-inflammatory signals like LPS, which achieved microbiota-neutrophil interactions (111).
4.3.2 Agaricus blazei Murill polysaccharides
Agaricus blazei Murill polysaccharides (ABPs) are the principal bioactive constituents of Agaricus blazei fruiting bodies, and ABP1 is the major component in ABPs. ABP1 increased the abundance of SCFA-producing bacteria, and promoted elevated butyrate levels, subsequently impeding neutrophil recruitment and modulating microbiota-neutrophil interactions (112).
4.4 Polyphenols
Polyphenols are a class of compounds widely present in natural products with multiple benzene rings and hydroxyl functional groups in their chemical structure, including flavonoids, flavonols, phenolic acids, phenylpropanoids, and anthocyanins. Polyphenols have a variety of pharmacological activities, containing antioxidant, anti-inflammatory, antibacterial and so on.
4.4.1 Forsythiaside A
Forsythiaside A, a phenylethanolic glycoside primarily isolated from Forsythia suspensa (Thunb.) Vahl, could downregulate the expression of PAD4 in colon neutrophils. This modulation led to a reduction in the levels of Cit-H3 and MPO, as well as in the expression of pro-inflammatory cytokines. Ultimately, the reduction attenuated the formation of NETs and alleviated colonic neutrophil infiltration (114).
4.4.2 Isochlorogenic acid A
Isochlorogenic acid A (ICGA-A), a dicaffeoylquinic acid, is abundantly present in various medicinal plants and vegetables. It has been shown to inhibit the STAT3/NF-κB pathway, then attenuating neutrophil activation and infiltration (115).
4.4.3 Chlorogenic acid
Chlorogenic acid (ChA) is a natural polyphenol predominantly found in coffee and various other plants. On one hand, it inhibited the NF-κB/p65 to decrease neutrophil infiltration (116, 168). On the other hand, it increased the relative abundance of Akkermansia in the intestine, and improved the integrity of the mucus layer through extracellular vesicles derived from Akkermansia mucosae (169). Concurrently, ChA inhibited the production of 4-HPA, interfered with JAK2/STAT3 signaling, and downregulated CXCL3 transcription, resulting in reduced recruitment of PMN-MDSC in CRC (117).
4.4.4 Curcumin
Curcumin, the bioactive natural polyphenol, is a substance derived from the rhizome of Curcuma longa. It reduced MPO activity, and limited the release of ROS (118, 119). Moreover, Curcumin exerted inhibitory effects on the activation of the Bcl-6-Syk-BLNK signaling pathway, promoted the conversion of naive B cells into memory B cells, restored the balance between pro-inflammatory and anti-inflammatory factors, and reduced CXCR3 expression. All contributed to a reduction in neutrophil recruitment to the colon (120, 170).
4.4.5 Astragalin
Astragalin (AG), a natural flavonoid found in Moringa oleifera, Radix astragali, Morus alba, and Cassia alata (171), suppressed NF-κB pathway, reduced the expression of pro-inflammatory cytokines, then inhibiting neutrophil infiltration in the colon. In addition, AG attenuated TLR4-mediated signaling, which was modulated by the abundance of intestine bacteria, leading to inhibiting neutrophil activation (121).
4.4.6 Hesperetin
Hesperetin, one of the major flavonoids with multiple biological activities, regulated the TLR4/NF-κB signaling pathway and concurrently inhibited the expression of LC3B, resulting in a reduced LC3-I/LC3-II ratio in neutrophils. In the meantime, Hesperetin decreased NETs formation and Cit-H3 production via the ROS/autophagy pathway (122).
4.4.7 Quercetin
Quercetin (QUE) is a natural flavonoid widely found in fruits and Chinese herbal medicines. Through activating AhR, QUE involved the upregulation of Arnt, reduced ROS and Nqo1 production, which caused an inhibition of NETs formation. Additionally, QUE has been observed to suppress IL-6 expression, decrease Th17 differentiation and neutrophil activation, thus mitigating tissue damage. It mitigated neutrophil-induced IECs apoptosis by inhibiting NF-κB activation and reducing PAD4-mediated NETosis, thereby modulating the detrimental “IECs-neutrophil” crosstalk (123, 124). Furthermore, QUE downregulated the expression of key inflammatory factors (IL1β, CXCL8, and MMP9), inhibiting neutrophil activation and infiltration, as well as suppressing tumor growth in CRC (125).
4.4.8 Dihydromyricetin
Dihydromyricetin, a flavonoid derived from the herb Ampelopsis grossedentata, targeted neutrophils and inhibited the HIF-1α/VEGFA signaling pathway, thus reducing the formation of NETs (126).
4.4.9 Kurarinone
Kurarinone, a major flavonoid compound from the dried roots of Sophora flavescens, restored gut microbiota and upregulated Blimp-1. These effects decreased IL-17A secretion by Th17 cells and increased IL-10 expression, preventing neutrophil infiltration and reducing neutrophil chemotaxis and activation (127).
4.4.10 Catechins
Green tea and black tea contain polyphenolic compounds, particularly catechins, such as epigallocatechin-3-gallate (EGCG). Catechins reduced TNF-α levels, significantly downregulated ICAM-1 and P-selectin expression, as well as decreased lipid peroxidation products like MDA. These actions inhibited ROS production and reduced neutrophil infiltration (128). EGCG suppressed NETs formation by modulating the STAT3/CXCL8 signaling pathway, afterwards inhibiting the migration and invasion of colorectal cancer (129).
4.4.11 Glabridin
Glabridin is a flavonoids compound isolated from Glycyrrhiza glabra L. It inhibited the phosphorylation of the transcription factor STAT3, leading to the downregulation of MMP1 and MMP3 expression. By suppressing MMPs, Glabridin decreased the release of CXCL1 and CXCL2, thus reducing neutrophil migration and infiltration (130).
4.4.12 Kaempferol
Kaempferol, a major flavonol widely found in various fruits and vegetables, downregulated the expression of key inflammatory mediators (IL-1β, CXCL8, and MMP9), then reducing neutrophil infiltration and activation while inhibiting tumor growth in CRC (125). Additionally, Kaempferol decreased TLR4/NF-κB pathway activation, which reduced the expression of chemokines and pro-inflammatory cytokines, subsequently inhibiting neutrophil infiltration in colitis (131).
4.5 Glycosides
Glycosides are compounds formed by the glycosidic linkage between the carbon atoms of sugar or sugar derivatives and non-sugar substances, which have antioxidant, anti-inflammatory, anti-cancer and other biological activities. According to the structural types of aglycones, they are most commonly divided into cyanogen glycosides, phenolic glycosides, alcohol glycosides, anthracene glycosides, flavone glycosides, saponins, cardiac glycosides, coumarin glycosides and iridoid glycosides.
4.5.1 Ursolic acid
Ursolic acid (UA), a naturally occurring pentacyclic triterpenoid carboxylic acid, is extracted from various medicinal plants and foods (172). UA has been shown to downregulate the PI3K signaling pathway, and suppress early immune responses triggered by neutrophils via the IL-6/STAT3 signaling pathway. It inhibited the activation of the NF-κB pathway, subsequently inhibiting the recruitment and activation of neutrophils at inflammation sites induced by chemokines. Furthermore, UA reduced ROS generated through activating the AMPK/FOXO signalling pathway in fatty acid metabolism. This multifaceted action alleviated oxidative stress mediated by neutrophils (132).
4.5.2 Glycyrrhizic acid
Glycyrrhizic acid (GA), a natural pentacyclic triterpenoid compound derived from licorice, could significantly reduce dsDNA, MPO-DNA complexes, ROS and Cit-H3 by inhibiting the enzymatic activity of PAD4. This action resulted in a marked decrease in the formation of NETs (133).
4.5.3 Anemoside B4
Anemoside B4 is the predominant triterpenoid saponin isolated from Pulsatilla chinensis. It decreased TLR4 activation by inhibiting S100A9 expression, subsequently suppressing the activation of MAPK (p38, JNK, ERK) and NF-κB signaling pathways. The effects resulted in suppressing the migration and accumulation of neutrophils in the colon directly or indirectly (134).
4.6 Terpenoids
Terpenoids are a general term for all polymers of isoprene and their derivatives, with a general formula (C5H8)n. In addition to existing as terpene hydrocarbons, they also form a wide variety of oxygen-containing derivatives. Terpenoids have diverse pharmacological activities, such as antibacterial, antitumor, anti-inflammatory, and coronary artery dilation.
4.6.1 Menthol and nerolidol
Menthol, a monocyclic monoterpene, serves as the primary active ingredient in the peppermint plant, while nerolidol is a naturally occurring aliphatic sesquiterpene alcohol. Both compounds have been demonstrated to reduce MPO activity, inhibit neutrophil activation, and diminish infiltration by enhancing tissue levels of SOD and CAT, reducing the formation of lipid peroxides and MDA, and restoring GSH bioavailability (135, 138).
4.6.2 Angelica oil
Volatile Angelica oil (AO) has been identified as a significant constituent of Angelica sinensis. AO mitigated the activation of the TLR4/NF-κB pathway, resulting in a reduction in cytokine production, simultaneously suppressing neutrophil infiltration in the colon (136).
4.6.3 Okanagan lavender essential oil
A unique blend of essential oils derived from lavender is referred to as Okanagan Lavender Essential Oil (OLEO). OLEO inhibited MIP-2α-mediated neutrophil infiltration into intestinal crypts (137).
4.6.4 Tripterygium wilfordii polycoride
Tripterygium wilfordii polycoride (TWP), the primary active compound of Tripterygium wilfordii, consists predominantly of diterpenoid and triterpenoid compounds. TWP has been demonstrated to significantly decrease NADPH oxidase activity and ROS production. It inhibited the activation of NLRP3 inflammasome, ASC and caspase-1, which ultimately reduced neutrophil infiltration via the inhibition of pyroptosis (139).
4.7 Microbiota-derived metabolites
4.7.1 Short-chain fatty acids
Short-chain fatty acids (SCFAs), major metabolites derived from gut microbiota, play a beneficial role in gastrointestinal health. The principal SCFAs, including acetate, propionate and butyrate, constitute more than 95% of the total SCFA content in feces.
4.7.1.1 Butyrate
By downregulating HDAC activity, butyrate reduced the release of MPO and ROS to inhibit the formation of NETs, and suppressed neutrophil migration induced by IL-8 (140). Meanwhile, butyrate suppressed NF-κB signaling pathway and the secretion of pro-inflammatory cytokines such as TNF-α with increased levels of MCP-1 and IL-6. These combined actions culminated in reduced neutrophil infiltration (141). For one thing, butyrate could induce neutrophil recruitment through the direct signaling of GPR43, for another, it could indirectly regulate neutrophils through the activation of other types of immune cells (142).
4.7.1.2 Acetate
Acetate upregulated CXCL2 protein expression and downregulated its receptor CXCR2 on colonic neutrophils, thereby inhibiting neutrophil recruitment and infiltration (143). It also delayed neutrophil apoptosis through FABP4 (110). Moreover, vitamin D encouraged the proliferation of acetate-producing bacteria, particularly Cetobacterium. The resulting increase in acetate enhanced IL-22 expression, which in turn stimulated neutrophil production (144).
4.7.2 Microalgae
Microalgae represent a diverse group of microorganisms that include diatoms, dinoflagellates, and flagellates. Microalgae reduced soybean meal-induced neutrophil infiltration by increasing goblet cell numbers and enhancing mucus secretion (145).
4.7.3 Altechromone A
Altechromone A could be isolated from the marine-derived fungus Penicillium chrysogenum (173). This compound inhibited both the STAT3 and NLRP3 pathways. This led to decreased expression of pro-inflammatory genes and reduced release of NO and ROS, resulting in limited neutrophil migration and accumulation (146).
4.8 Natural medicinal materials
4.8.1 Aucklandiae Radix
In Chinese Pharmacopoeia, costunolide is the principal active constituent of Aucklandiae Radix. It promoted the differentiation of Treg cells and reduced the differentiation of Th17 cells through downregulating PKM2 expression, which subsequently diminished the accumulation of neutrophils in the intestinal tract (147).
4.8.2 Tiliae Flos
The pharmacological activity of Tiliae Flos is primarily attributed to its flavonoid, saponin, and phenolic acid constituents. Its extract has been shown to elevate SCFA levels, inhibit NF-κB signaling, and suppress TNF-α production, inducing neutrophil apoptosis (148).
4.8.3 Phyllanthus niruri Linn
Phyllanthus niruri Linn comprises active phytochemicals in various parts, including flavonoids, alkaloids, terpenoids, lignin, polyphenols, tannins, coumarin and saponins. It increased the expression of cytotoxic T lymphocytes and NK cells, also elevated the number of apoptotic cells to reduce respiratory burst and the release of TNF-α and interferon-induced proteins. Collectively, the process finally inhibited the pro-inflammatory functions of intestinal neutrophils (149).
4.8.4 Cicer arietinum L.
Cicer arietinum L. (CEE) is known for its high lysine content. The ethanol extract of CEE inhibited NF-κB/STAT3 signaling pathways, causing reduced expression of IL-6, IL-1β, TNF-α, COX-2 and iNOS, and ultimately inhibiting neutrophil activation (150).
4.8.5 Black raspberries
Black raspberries are rich in soluble fiber, which undergoes colonic fermentation to produce SCFAs. It upregulated FFAR2 expression and inhibited both the cAMP-PKA-CREB and Wnt signaling pathways, resulting in decreased infiltration of GR-1+ neutrophils within intestinal polyps (151).
4.8.6 Fritillariae thunbergii Bulbus
Phytochemical investigations of Fritillariae thunbergii Bulbus (FTB) have identified several bioactive alkaloids, containing sipeimine, peiminine, and yibeissine. Hydroethanolic extract of FTB decreased neutrophil infiltration into intestinal tissues and modulated extracellular matrix remodeling by suppressing MMP-9 activity during inflammation (152).
4.8.7 Ilex rotunda Thunb.
Ziyuglycoside I, Ziyuglycoside II, syringin, and pedunculoside are the main active components of Ilex rotunda Thunb. (IR). The primary active components downregulated the expression of OSM and OSMR proteins, inhibiting the activation of STAT3 pathway. IR also suppressed the TLR4/NF-κB signaling pathway, thus mitigating neutrophil activation and infiltration (153).
4.8.8 Hydroalcoholic extract of Araucaria sp.
Araucaria sp. is a hypropolis species particularly rich in labdane diterpenes. Its hydroalcoholic extract attenuated oxidative stress by reducing lipid peroxidation and preserving GST enzyme activity, along with inhibiting MPO activity and chemotactic migration, thereby leading to a significant reduction in neutrophil numbers (154).
4.8.9 Bixa orellana leaf hydroethanolic extract
The hydroethanolic extract of Bixa orellana modulated oxidative stress through the direct scavenging of ROS or inhibition of cyclooxygenase and lipoxygenase enzymes, contributing to a reduction in neutrophil infiltration (155).
4.8.10 A phytopharmaceutical combining sage and bitter apple
A phytopharmaceutical combining sage and bitter apple reduced the expression of neutrophil chemokine CXCL1/KC in colon tissue. It also inhibited MPO activity and the expression of pro-inflammatory cytokines and chemokines, promoted expression of the anti-inflammatory cytokines, which further mitigated neutrophil infiltration (156).
4.9 Traditional Chinese medicine compounds
4.9.1 Wu-Mei-Wan
Wu-Mei-Wan formula reduced RIPK3 activation, necrosome formation, and the levels of IL-1β, IL-6, TNF-α and IFN-γ to inhibit neutrophil necrotic apoptosis and neutrophil infiltration (157).
4.9.2 Huang Qin decoction
Huang Qin Decoction inhibited the formation of NETs by downregulating the expression of PAD4. Besides, it alleviated neutrophil infiltration in the colon caused by TNF-α and IL-1β (158).
4.9.3 Qu-Yu-Jie-Du decoction
Qu-Yu-Jie-Du Decoction downregulated the expression of CCL2 and CXCL2 in colon tissues, then reducing local neutrophil infiltration (159).
4.9.4 Huanglian Ganjiang decoction
Alkaloids such as berberine, berberrubine, oxyberberine are the main ingredients in cold-natured medicine CP extracts in Huanglian Ganjiang Decoction. By contrast, volatile oil is the main active constituent in hot-natured medicine AZ. CP reduced production of pro-inflammatory cytokines and neutrophil infiltration while AZ exerted advantages in regulating neutrophils by enhancing the production of anti-inflammatory immune cells and cytokines (160).
4.9.5 Pulsatilla decoction
Pulsatilla decoction (PD) reduced MMP-7 expression and decreased neutrophil infiltration to suppress intestinal inflammation (161). Simultaneously, the n-butanol extract of PD reduced the levels of chemokines CXCL1 and CXCL2, inhibited Ly6G expression and ROS generation, effectively decreasing neutrophil infiltration and activation. It led to the suppression of key proteins involved in NETs formation (MPO, PAD4, Cit-H3), resulting in diminished NETs release (162).
4.9.6 Sijunzi decoction
The practical components of Sijunzi Decoction (SJZ) may be ginsenoside Rh2, isoflavones and formononetin. SJZ targeted IL1β and TNF to decrease ROS production and reduced intestinal NETs formation. Meanwhile, it upregulated MIR200C-3p, enhancing intestinal mucosal barrier function and reducing neutrophil infiltration (163).
4.10 Additional information
To facilitate a systematic comparison of therapeutic effects, the aforementioned natural products are categorized according to their respective mechanisms of action (Supplementary Table 1). The classification is based primarily on neutrophil-related functional regulatory pathways, including ROS production, NETs formation, degranulation, secretion of inflammatory factors (thereby stimulating other immune cells), neutrophil apoptosis or pyroptosis, chemotaxis, tissue infiltration, and recruitment. Furthermore, experimental data from multiple models involving these natural products have been consolidated (Supplementary Table 2), revealing their dose–response relationships and toxicity profiles. Natural products typically exhibit multi-target and synergistic regulatory features, with ROS, NETs, and the NF-κB pathway representing the core regulatory mechanisms involved. In contrast, research on other regulatory pathways remains relatively limited. The collected studies primarily consisted of in vivo animal experiments using various administration routes, among which oral administration was the most common. Nevertheless, comprehensive safety evaluations—particularly detailed toxicity profiles—are still lacking for most of these natural products, highlighting a significant gap that warrants further investigation. The compiled information is expected to provide a valuable reference for future drug development and mechanistic studies.
5 Novel therapeutic strategies targeting neutrophils
5.1 Based on nanotechnology
5.1.1 Nanomedicine delivery systems
Neutrophils have been widely used in developing various drug-delivery systems because they can quickly respond to inflammatory signals, migrate across the endothelium, and penetrate deep tissues (174, 175). In recent years, neutrophil-targeted nanodrug precise delivery systems have emerged. Notably, promising results have been observed in models of IBD and CRC (Figure 4).
Figure 4. The figure illustrates the latest methods of regulating neutrophil function through nanotechnology and engineered cell strategies.
Receptor-mediated neutrophil targeting.
Another strategy is receptor-mediated targeting. By modifying the surface of drug carriers with ligands that bind to specific markers on neutrophils, drugs can be directly delivered to neutrophils in circulation or at sites of inflammation, thereby exploiting neutrophils for drug transport (176). The strategy demonstrated that targeting neutrophil receptors or enzymes can significantly enhance delivery precision. Drugs are released only around activated neutrophils under disease conditions, thereby avoiding broad immunosuppression of resting neutrophils.
Extracellular vesicles.
Extracellular vesicles (EVs) are nanoscale vesicles secreted by cells that can carry proteins, lipids, and nucleic acids, playing crucial roles in intercellular communication and immune regulation (177). EVs, owing to their stability and biocompatibility, can enhance the stability of natural products and prevent their rapid degradation in vivo (177). A typical example is exosome-like nanoparticles derived from Coptidis chinensis (Cc-ELNs). In a DSS-induced colitis mouse model, Cc-ELNs selectively accumulated at inflammatory sites, significantly reduced neutrophil infiltration, and effectively inhibited NETs formation by delivering abundant miR-5106 to downregulate Slc39a2 expression and restore zinc homeostasis in neutrophils (178). In addition, Yang Yi et al. reported that outer membrane vesicles secreted by the gut commensal Bacteroides fragilis can be taken up by neutrophils. By delivering miR-5119, they downregulate PD-L1 expression, which inhibits GSDMD-mediated NETs formation, ultimately alleviating DSS-induced colitis symptoms and promoting intestinal stem cell repair (179). This finding revealed a unique mechanism by which microbe-derived vesicles intervene in inflammation through the regulation of NETs formation.
Other nanodrug delivery systems.
As research progresses, an increasing number of nanodrug delivery systems have been developed, including self-assembled nanodelivery systems of natural products, nanosuspensions, nanoliposomes, polymeric micelles, microemulsions/self-emulsifying systems, and solid lipid nanoparticles (180, 181). Importantly, many of these nanosystems exhibit preferential accumulation in inflamed intestinal tissues.
As an example, during decoction, the traditional Chinese medicine formula QY305 can self-assemble into nanoscale subunit structures termed N-QY305, which could inhibit neutrophil chemotaxis toward CXCL2 in colonic tissues (180). Similarly, binary self-assembly of curcumin and glycyrrhizic acid into nanospheres, when incorporated into an inulin hydrogel for oral administration, exhibits favorable gel formation and colon enzyme-triggered drug release (182). Although the application of these technologies in neutrophil-targeted therapy is still nascent, integrating natural product-based nanodelivery systems with neutrophil-targeted carriers represents a promising future direction for the treatment of intestinal disorders such as IBD and even CRC (181).
5.1.2 Other nanotechnologies
Beyond conventional nanodrug delivery, emerging nanotechnology strategies aimed at clearing NETs show therapeutic potential. While DNase I can degrade NETs and alleviate intestinal inflammation, its clinical utility is limited by intrinsic instability and rapid clearance. To overcome these limitations, Wang et al. developed a stable DNase nanozyme (DNase-NZ) that retained prolonged enzymatic activity and exerted superior efficacy in colitis mice compared to free DNase (183). In a similar vein, Dong et al. designed an oral delivery system for staphylococcal nuclease (SNase) that enabled localized NETs degradation in the colon and promoted mucosal repair (184). These advances underscore the promise of nanotechnology-enabled NETs clearance as an adjunctive therapy for intestinal immune disorders.
5.2 Engineered cell drug delivery
Engineered neutrophil-based drug delivery leverages multidisciplinary strategies to transform these cells into sophisticated therapeutic carriers. Key innovations are as follows: Genetic engineering, exemplified by generating chimeric antigen receptor-expressing neutrophils from human-induced pluripotent stem cells via CRISPR/Cas9, enable specific tumor targeting without provoking inflammation (185). Chemical and surface modification, where small molecules or conjugated functional groups are used to extend neutrophil lifespan and enhance targeting precision (186, 187). Functional mimicry, such as introducing artificial receptors like hM4Di into myeloid cells to bestow chemotactic responsiveness to inert ligands, thereby augmenting directional migration and bacterial phagocytosis (188). By integrating active targeting, programmable drug release, and intrinsic immune functions, these engineered or neutrophil-mimetic cells achieved amplified specificity, reduced off-target effects, and improved therapeutic efficacy compared with conventional nanocarriers.
6 Discussion
This review has systematically summarized the compelling evidence that numerous natural products can precisely modulate the plasticity and function of intestinal neutrophils, thereby ameliorating inflammation and tissue damage in conditions such as IBD and CRC. The extraction of alkaloids, quinones, polysaccharides, polyphenols, glycosides, terpenoids, microbiota-derived metabolites compounds from natural sources has been investigated. We detail their multi-targeted influences on key neutrophil processes, encompassing migration, NETs formation, cytokine release, and oxidative metabolism. Furthermore, we have discussed the underlying molecular mechanisms behind these immunomodulatory actions, as well as the potential of emerging neutrophil-targeted strategies, to enhance the delivery and efficacy of natural products.
The bidirectional regulation of neutrophil function by natural compounds still faces multifaceted challenges in translating from basic biological research to clinical applications. Despite recent advances in single-cell sequencing that have identified several functionally distinct neutrophil subsets in the intestinal mucosa, our understanding of neutrophil heterogeneity remains incomplete, particularly with regard to the dynamic mechanisms and regulatory circuits governing their phenotypic plasticity under different disease contexts (10, 43). Current data derive primarily from limited disease models and tissue sources, necessitating more comprehensive single-cell analyses across diverse intestinal immune disorders. The precise relationship between circulation and tissue-resident intestinal neutrophils remains inadequately defined, with insufficient evidence on their trafficking dynamics and functional transitions. Moreover, the regulatory mechanisms governing neutrophil maturation and phenotypic specialization within the intestinal microenvironment require further investigation.Additionally, several challenges remain. The lack of clear definitions of bioavailability, metabolic conversion, effective tissue concentration, and precise molecular targets hinders their clinical translation.
Nevertheless, natural product research targeting intestinal neutrophils remains relatively conservative and limited in scope. The therapeutic mode of action for natural products is characterized by multi-target network regulation, yet the systematic mapping of their mechanism networks remains in its infancy (189). Indeed, research primarily focuses on superficial interactions between the gut microbiota, the epithelial, and neutrophils, with restricted exploration of interactions involving other immune cells. Next, therapeutic mechanisms continue to be narrowly concentrated on key targets such as NETs, NF-κB inflammatory cascades, pyroptosis and oxidative stress. Lastly, research on novel delivery methods for natural products targeting neutrophils remains scarce. In current studies, the common approach is to use conventional oral or injectable administration routes, and there is little exploration of innovative delivery methods like nanocarriers and targeted delivery systems for regulating neutrophils with natural products. The status quo imposes limitations on the potential of natural products in the treatment of intestinal immune disorders. It is imperative that further research be conducted on innovative delivery methods with a view to broadening their clinical application prospects.
Looking forward, future research should focus on several key directions. First, a deeper understanding of the molecular mechanisms governing neutrophil heterogeneity and natural product interactions is essential. Mechanistic investigations must advance beyond phenomenological observations to elucidate the molecular determinants of neutrophil heterogeneity and the precise interaction networks through which natural products exert their immunomodulatory effects (10, 43). Second, the integration of compounds with cutting-edge biotechnologies faces inherent challenges, including inherent heterogeneity, lack of standardized separation and characterization protocols, unclear in vivo pharmacokinetics, and obstacles in scalable production and storage stability (190, 191). Advanced delivery systems should be optimized to enhance the specificity and accuracy of drug delivery to the intestinal neutrophil, and to ensure functionality, sustained safety and stability (183, 184). Third, rigorous preclinical and clinical studies are needed to validate the efficacy and safety of natural products, either as monotherapies or in combination with conventional treatments (192, 193). Collectively, natural products represent a valuable resource for developing next-generation neutrophil-targeted therapies. These suggestions might usher in a new paradigm of developing novel therapies targeting intestinal neutrophils for patients.
7 Conclusion
This review summarizes the heterogeneity and plasticity of intestinal neutrophils and their dynamic interactions with the microbiota, epithelial barrier, and other immune cells. We compile current evidence demonstrating how natural products modulate neutrophil activation, migration, NETs formation, inflammatory signaling, pyroptosis, and oxidative stress. We further evaluate the therapeutic efficacy and safety of natural products, and highlight emerging neutrophil-targeted technologies to enhance the delivery and efficacy. Collectively, these findings highlight the significant potential of natural products as integrative immunomodulatory interventions targeting intestinal neutrophils.
Author contributions
RK: Writing – original draft, Writing – review & editing. AS: Writing – original draft, Writing – review & editing. JY: Writing – review & editing, Writing – original draft, Data curation. LC: Data curation, Writing – original draft. WS: Data curation, Writing – original draft. YC: Funding acquisition, Writing – review & editing, Supervision. FK: Funding acquisition, Writing – review & editing, Supervision.
Funding
The author(s) declared that financial support was received for this work and/or its publication. The authors and their work were supported by National Natural Science Foundation of China for Young Scientists (No. 82305143, No. 82505431), National Natural Science Foundation of China-Youth Science Foundation Funding Matching Project (No: XPT82305143), the first batch of the “Double Hundred Plan”(Academic Experience Inheritance Project for Renowned Traditional Chinese Medicine Experts) of Nanjing University of Chinese Medicine (013062024003-22).
Conflict of interest
The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1754107/full#supplementary-material
References
1. Neurath MF. Strategies for targeting cytokines in inflammatory bowel disease. Nat Rev Immunol. (2024) 24:559–76. doi: 10.1038/s41577-024-01008-6
2. Danne C, Skerniskyte J, Marteyn B, and Sokol H. Neutrophils: from IBD to the gut microbiota. Nat Rev Gastroenterol Hepatol. (2024) 21:184–97. doi: 10.1038/s41575-023-00871-3
3. Kang L, Fang X, Song YH, He ZX, Wang ZJ, Wang SL, et al. Neutrophil-epithelial crosstalk during intestinal inflammation. Cell Mol Gastroenterol Hepatol. (2022) 14:1257–67. doi: 10.1016/j.jcmgh.2022.09.002
4. Khoyratty TE, Ai Z, Ballesteros I, Eames HL, Mathie S, Martín-Salamanca S, et al. Distinct transcription factor networks control neutrophil-driven inflammation. Nat Immunol. (2021) 22:1093–106. doi: 10.1038/s41590-021-00968-4
5. Friedrich M, Pohin M, Jackson MA, Korsunsky I, Bullers SJ, Rue-Albrecht K, et al. IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies. Nat Med. (2021) 27:1970–81. doi: 10.1038/s41591-021-01520-5
6. Ballesteros I, Rubio-Ponce A, Genua M, Lusito E, Kwok I, Fernández-Calvo G, et al. Co-option of neutrophil fates by tissue environments. Cell. (2020) 183:1282–1297.e18. doi: 10.1016/j.cell.2020.10.003
7. Kramer ED, Tzetzo SL, Colligan SH, Hensen ML, Brackett CM, Clausen BE, et al. β-Catenin signaling in alveolar macrophages enhances lung metastasis through a TNF-dependent mechanism. JCI Insight. (2023) 8:e160978. doi: 10.1172/jci.insight.160978
8. Xu Q, Zhao W, Yan M, and Mei H. Neutrophil reverse migration. J Inflammation (Lond). (2022) 19:22. doi: 10.1186/s12950-022-00320-z
9. Garrido-Trigo A, Corraliza AM, Veny M, Dotti I, Melon-Ardanaz E, Rill A, et al. Macrophage and neutrophil heterogeneity at single-cell spatial resolution in human inflammatory bowel disease. Nat Commun. (2023) 14:4506. doi: 10.1038/s41467-023-40156-6
10. Ganesh K and Joshi MB. Neutrophil sub-types in maintaining immune homeostasis during steady state, infections and sterile inflammation. Inflammation Res. (2023) 72:1175–92. doi: 10.1007/s00011-023-01737-9
11. Liu J, Di B, and Xu LL. Recent advances in the treatment of IBD: Targets, mechanisms and related therapies. Cytokine Growth Fac Rev. (2023) 71-72:1–12. doi: 10.1016/j.cytogfr.2023.07.001
12. Martling A, Hed Myrberg I, Nilbert M, Grönberg H, Granath F, Eklund M, et al. Low-dose aspirin for PI3K-altered localized colorectal cancer. New Engl J Med. (2025) 393:1051–64. doi: 10.1056/nejmoa2504650
13. Ahmed W, Galati J, Kumar A, Christos PJ, Longman R, Lukin DJ, et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. (2022) 20:e361–79. doi: 10.1016/j.cgh.2021.03.034
14. Singh S, Velayos FS, and Rubin DT. Common instances of low-value care in inflammatory bowel diseases. Clin Gastroenterol Hepatol. (2024) 22:923–32. doi: 10.1016/j.cgh.2023.09.043
15. Greuter T, Rieder F, Kucharzik T, Peyrin-Biroulet L, Schoepfer AM, Rubin DT, et al. Emerging treatment options for extraintestinal manifestations in IBD. Gut. (2021) 70:796–802. doi: 10.1136/gutjnl-2020-322129
16. Gros B, Constantine-Cooke N, Kennedy J, Elford AT, O’Hare C, Noble C, et al. Tofacitinib versus vedolizumab among bio-naive patients with ulcerative colitis: A real-world propensity-weighted comparison. J CD Col. (2025) 19:jjae188. doi: 10.1093/ecco-jcc/jjae188
17. Shahzad A, Ni Y, Yang Y, Liu W, Teng Z, Bai H, et al. Neutrophil Extracellular Traps (NETs) in health and disease. Mol Biomed. (2025) 6:130. doi: 10.1186/s43556-025-00337-9
18. Luo X, Chang S, Xiao S, Peng Y, Gao Y, Hu F, et al. PAD4-dependent citrullination of nuclear translocation of GSK3β promotes colorectal cancer progression via the degradation of nuclear CDKN1A. Neoplasia. (2022) 33:100835. doi: 10.1016/j.neo.2022.100835
19. Li Y, Wu S, Zhao Y, Dinh T, Jiang D, Selfridge JE, et al. Neutrophil extracellular traps induced by chemotherapy inhibit tumor growth in murine models of colorectal cancer. J Clin Invest. (2024) 134:e175031. doi: 10.1172/jci175031
20. Zhang R, Tan Y, Jiang D, Kong D, Liu M, Liang J, et al. Anoikis and NETosis in colorectal cancer liver metastasis: the relationship and perspectives. Biochim Biophys Acta (BBA) - Rev Cancer. (2025) 1880:189401. doi: 10.1016/j.bbcan.2025.189401
21. Zeng W, Song Y, Wang R, He R, and Wang T. Neutrophil elastase: From mechanisms to therapeutic potential. J Pharm Anal. (2023) 13:355–66. doi: 10.1016/j.jpha.2022.12.003
22. Tan H, Jiang Y, Shen L, Nuerhashi G, Wen C, Gu L, et al. Cryoablation-induced neutrophil Ca2+ elevation and NET formation exacerbate immune escape in colorectal cancer liver metastasis. J Exp Clin Cancer Res. (2024) 43:319. doi: 10.1186/s13046-024-03244-z
23. Chen J, Hou S, Liang Q, He W, Li R, Wang H, et al. Localized degradation of neutrophil extracellular traps by photoregulated enzyme delivery for cancer immunotherapy and metastasis suppression. ACS Nano. (2022) 16:2585–97. doi: 10.1021/acsnano.1c09318
24. Zu M, Ma Y, Cannup B, Xie D, Jung Y, Zhang J, et al. Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases. Adv Drug Delivery Rev. (2021) 176:113887. doi: 10.1016/j.addr.2021.113887
25. Wang M, Wang Z, Li Z, Qu Y, Zhao J, Wang L, et al. Targeting programmed cell death in inflammatory bowel disease through natural products: New insights from molecular mechanisms to targeted therapies. Phytother Res. (2025) 39:1776–807. doi: 10.1002/ptr.8216
26. Manoj H, Gomes SM, Thimmappa PY, Nagareddy PR, Jamora C, and Joshi MB. Cytokine signalling in formation of neutrophil extracellular traps: Implications for health and diseases. Cytokine Growth Fac Rev. (2025) 81:27–39. doi: 10.1016/j.cytogfr.2024.12.001
27. Vaghari-Tabari M, Alemi F, Zokaei M, Moein S, Qujeq D, Yousefi B, et al. Polyphenols and inflammatory bowel disease: Natural products with therapeutic effects? Crit Rev Food Sci Nutr. (2024) 64:4155–78. doi: 10.1080/10408398.2022.2139222
28. Xie X, Liu M, Zhang Y, Wang B, Zhu C, Wang C, et al. Single-cell transcriptomic landscape of human blood cells. Natl Sci Rev. (2020) 8:nwaa180. doi: 10.1093/nsr/nwaa180
29. Dumont BL, Neagoe P-E, Charles E, Villeneuve L, Ninni S, Tardif J-C, et al. Low-density neutrophils and neutrophil extracellular traps (NETs) are new inflammatory players in heart failure. Can J Cardiol. (2024) 40:1524–35. doi: 10.1016/j.cjca.2024.03.018
30. Fu Y, Wen Z, and Fan J. Interaction of low-density neutrophils with other immune cells in the mechanism of inflammation. Mol Med. (2025) 31:133. doi: 10.1186/s10020-025-01187-5
31. Bashant KR, Aponte AM, Randazzo D, Rezvan Sangsari P, Wood AJ, Bibby JA, et al. Proteomic, biomechanical and functional analyses define neutrophil heterogeneity in systemic lupus erythematosus. Ann Rheum Dis. (2021) 80:209–18. doi: 10.1136/annrheumdis-2020-218338
32. Cho Y, Bukong TN, Tornai D, Babuta M, Vlachos IS, Kanata E, et al. Neutrophil extracellular traps contribute to liver damage and increase defective low-density neutrophils in alcohol-associated hepatitis. J Hepatol. (2023) 78:28–44. doi: 10.1016/j.jhep.2022.08.029
33. Antuamwine BB, Bosnjakovic R, Hofmann-Vega F, Wang X, Theodosiou T, Iliopoulos I, et al. N1 versus N2 and PMN-MDSC: A critical appraisal of current concepts on tumor-associated neutrophils and new directions for human oncology. Immunol Rev. (2022) 314:250–79. doi: 10.1111/imr.13176
34. Silvestre-Roig C, Fridlender ZG, Glogauer M, and Scapini P. Neutrophil diversity in health and disease. Trends Immunol. (2019) 40:565–83. doi: 10.1016/j.it.2019.04.012
35. Chen H, Wu X, Sun R, Lu H, Lin R, Gao X, et al. Dysregulation of CD177+ neutrophils on intraepithelial lymphocytes exacerbates gut inflammation via decreasing microbiota-derived DMF. Gut Microbes. (2023) 15:2172668. doi: 10.1080/19490976.2023.2172668
36. Seo DH, Che X, Kim S, Kim DH, Ma HW, Kim JH, et al. Triggering receptor expressed on myeloid cells-1 agonist regulates intestinal inflammation via cd177+ Neutrophils. Front Immunol. (2021) 12:650864. doi: 10.3389/fimmu.2021.650864
37. Huber A, Jose S, Kassam A, Weghorn KN, Powers-Fletcher M, Sharma D, et al. Olfactomedin-4+neutrophils exacerbate intestinal epithelial damage and worsen host survival afterClostridioides difficileinfection (2023). doi: 10.1101/2023.08.21.553751
38. Naveh CA, Roberts K, Zakrzewski P, Rice CM, Ponce-Garcia FM, Fleming K, et al. Neutrophils cultured ex vivo from CD34+ stem cells are immature and genetically tractable. J Trans Med. (2024) 22:526. doi: 10.1186/s12967-024-05337-x
39. Fouret P, du Bois RM, Bernaudin JF, Takahashi H, Ferrans VJ, and Crystal RG. Expression of the neutrophil elastase gene during human bone marrow cell differentiation. J Exp Med. (1989) 169:833–45. doi: 10.1084/jem.169.3.833
40. Drury B, Hardisty G, Gray RD, and Ho GT. Neutrophil extracellular traps in inflammatory bowel disease: pathogenic mechanisms and clinical translation. Cell Mol Gastroenterol Hepatol. (2021) 12:321–33. doi: 10.1016/j.jcmgh.2021.03.002
41. Chen H, Wu X, Xu C, Lin J, and Liu Z. Dichotomous roles of neutrophils in modulating pathogenic and repair processes of inflammatory bowel diseases. Prec Clin Med. (2021) 4:246–57. doi: 10.1093/pcmedi/pbab025
42. Li T, Wang C, Liu Y, Li B, Zhang W, Wang L, et al. Neutrophil extracellular traps induce intestinal damage and thrombotic tendency in inflammatory bowel disease. J CD Col. (2020) 14:240–53. doi: 10.1093/ecco-jcc/jjz132
43. Zhang C, Zhang J, Zhang Y, Song Z, Bian J, Yi H, et al. Identifying neutrophil-associated subtypes in ulcerative colitis and confirming neutrophils promote colitis-associated colorectal cancer. Front Immunol. (2023) 14:1095098. doi: 10.3389/fimmu.2023.1095098
44. Salas A, Hernandez-Rocha C, Duijvestein M, Faubion W, McGovern D, Vermeire S, et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. (2020) 17:323–37. doi: 10.1038/s41575-020-0273-0
45. Zhou G, Yu L, Fang L, Yang W, Yu T, Miao Y, et al. CD177+ neutrophils as functionally activated neutrophils negatively regulate IBD. Gut. (2018) 67:1052–63. doi: 10.1136/gutjnl-2016-313535
46. Chen J, Bai Y, Xue K, Li Z, Zhu Z, Li Q, et al. CREB1-driven CXCR4hi neutrophils promote skin inflammation in mouse models and human patients. Nat Commun. (2023) 14:5894. doi: 10.1038/s41467-023-41484-3
47. Ardi VC, Kupriyanova TA, Deryugina EI, and Quigley JP. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci U S A. (2007) 104:20262–7. doi: 10.1073/pnas.0706438104
48. Lin J, Li G, Xu C, Lu H, Zhang C, Pang Z, et al. Monocyte chemotactic protein 1-induced protein 1 is highly expressed in inflammatory bowel disease and negatively regulates neutrophil activities. Mediators Inflammation. (2020) 2020:8812020. doi: 10.1155/2020/8812020
49. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. (2009) 16:183–94. doi: 10.1016/j.ccr.2009.06.017
50. Mishalian I, Bayuh R, Levy L, Zolotarov L, Michaeli J, and Fridlender ZG. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol Immunother. (2013) 62:1745–56. doi: 10.1007/s00262-013-1476-9
51. Yu R, Zhu B, and Chen D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell Mol Life Sci. (2022) 79:191. doi: 10.1007/s00018-022-04219-z
52. Andzinski L, Kasnitz N, Stahnke S, Wu CF, Gereke M, von Köckritz-Blickwede M, et al. Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int J Cancer. (2016) 138:1982–93. doi: 10.1002/ijc.29945
53. Pylaeva E, Harati MD, Spyra I, Bordbari S, Strachan S, Thakur BK, et al. NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophils. Int J Cancer. (2019) 144:136–49. doi: 10.1002/ijc.31808186
54. Kong X, Zhang Y, Xiang L, You Y, Duan Y, Zhao Y, et al. Fusobacterium nucleatum-triggered neutrophil extracellular traps facilitate colorectal carcinoma progression. J Exp Clin Cancer Res. (2023) 42:236. doi: 10.1186/s13046-023-02817-8
55. Gül E, Enz U, Maurer L, Abi Younes A, Fattinger SA, Nguyen BD, et al. Intraluminal neutrophils limit epithelium damage by reducing pathogen assault on intestinal epithelial cells during Salmonella gut infection. PloS Pathog. (2023) 19:e1011235. doi: 10.1371/journal.ppat.1011235
56. Fachi JL, Oliveira S, Gilfillan S, Antonova AU, Hou J, Vinolo MAR, et al. NKp46+ ILC3s promote early neutrophil defense against Clostridioides difficile infection through GM-CSF secretion. Proc Natl Acad Sci U.S.A. (2024) 121:e2416182121. doi: 10.1073/pnas.2416182121
57. Zhou Z, Yang W, Yu T, Yu Y, Zhao X, Yu Y, et al. GPR120 promotes neutrophil control of intestinal bacterial infection. Gut Microbes. (2023) 15:2190311. doi: 10.1080/19490976.2023.2190311
58. Dong D, Su T, Chen W, Wang D, Xue Y, Lu Q, et al. Clostridioides difficile aggravates dextran sulfate solution (DSS)-induced colitis by shaping the gut microbiota and promoting neutrophil recruitment. Gut Microbes. (2023) 15:2192478. doi: 10.1080/19490976.2023.2192478
59. Stein K, Lysson M, Schumak B, Vilz T, Specht S, Heesemann J, et al. Leukocyte-derived interleukin-10 aggravates postoperative ileus. Front Immunol. (2018) 9:2599. doi: 10.3389/fimmu.2018.02599
60. Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Danese S, et al. Assessment and grading of mucosal inflammation in colonic diverticular disease. J Clin Gastroenterol. (2008) 42:699–703. doi: 10.1097/MCG.0b013e3180653ca2
61. Tursi A, Elisei W, Giorgetti GM, Inchingolo CD, Nenna R, Picchio M, et al. Expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor α in resected acute colonic diverticulitis. Col Dis. (2014) 16:O98–O103. doi: 10.1111/codi.12504
62. Tursi A, Elisei W, Brandimarte G, Giorgetti GM, and Aiello F. Predictive value of serologic markers of degree of histologic damage in acute uncomplicated colonic diverticulitis. J Clin Gastroenterol. (2010) 44:702–6. doi: 10.1097/MCG.0b013e3181dad979
63. Burn GL, Foti A, Marsman G, Patel DF, and Zychlinsky A. The neutrophil. Immunity. (2021) 54:1377–91. doi: 10.1016/j.immuni.2021.06.006
64. Biasi F, Leonarduzzi G, Oteiza PI, and Poli G. Inflammatory bowel disease: mechanisms, redox considerations, and therapeutic targets. Antiox Redox Signal. (2013) 19:1711–47. doi: 10.1089/ars.2012.4530
65. Wu J, Dong W, Pan Y, Wang J, Wu M, and Yu Y. Crosstalk between gut microbiota and metastasis in colorectal cancer: implication of neutrophil extracellular traps. Front Immunol. (2023) 14:1296783. doi: 10.3389/fimmu.2023.1296783
66. Winter SE, Winter MG, Xavier MN, Thiennimitr P, Poon V, Keestra AM, et al. Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science. (2013) 339:708–11. doi: 10.1126/science.1232467
67. Angelo Z, Riccardo B, Simonetta F, Incà Renata D, Carlo SG, Viviana C, et al. Inflammasome activation P2X7-dependent in crohn’s disease. J GI Dig Syst. (2015) 5:316. doi: 10.4172/2161-069X.1000316
68. Jiang D, Zhang J, Lin S, Wang Y, Chen Y, and Fan J. Prolyl endopeptidase gene disruption improves gut dysbiosis and non-alcoholic fatty liver disease in mice induced by a high-fat diet. Front Cell Dev Biol. (2021) 9:628143. doi: 10.3389/fcell.2021.628143
69. Palrasu M, Kakar K, Marudamuthu A, Hamida H, Thada S, Zhong Y, et al. AhR activation transcriptionally induces anti-microbial peptide alpha-defensin 1 leading to reversal of gut microbiota dysbiosis and colitis. Gut Microbes. (2025) 17:2460538. doi: 10.1080/19490976.2025.2460538
70. Zechner EL. Inflammatory disease caused by intestinal pathobionts. Curr Opin Microbiol. (2017) 35:64–9. doi: 10.1016/j.mib.2017.01.011
71. Li Q, Xiao Y, Han L, Luo W, Dai W, Fang H, et al. Microbiome dysbiosis, neutrophil recruitment and mesenchymal transition of mesothelial cells promotes peritoneal metastasis of colorectal cancer. Nat Cancer. (2025) 6:493–510. doi: 10.1038/s43018-025-00910-9
72. Wang J, Zhu N, Su X, Gao Y, and Yang R. Gut-microbiota-derived metabolites maintain gut and systemic immune homeostasis. Cells. (2023) 12:793. doi: 10.3390/cells12050793
73. Wu M, Zheng W, Song X, Bao B, Wang Y, Ramanan D, et al. Gut complement induced by the microbiota combats pathogens and spares commensals. Cell. (2024) 187:897–913.e18. doi: 10.1016/j.cell.2023.12.036
74. Wang LL, Shen X, Xie Y, Ge A, Lu H, Gu S, et al. A gut Eggerthella lenta-derived metabolite impairs neutrophil function to aggravate bacterial lung infection. Sci Transl Med. (2025) 17:eadq4409. doi: 10.1126/scitranslmed.adq4409
75. Zhu Z, Huang J, Zhang Y, Hou W, Chen F, Mo YY, et al. Landscape of tumoral ecosystem for enhanced anti-PD-1 immunotherapy by gut Akkermansia muciniphila. Cell Rep. (2024) 43:114306. doi: 10.1016/j.celrep.2024.114306
76. Nascimento M, Huot-Marchand S, Fanny M, Straube M, Le Bert M, Savigny F, et al. NLRP6 controls pulmonary inflammation from cigarette smoke in a gut microbiota-dependent manner. Front Immunol. (2023) 14:1224383. doi: 10.3389/fimmu.2023.1224383
77. Liu T, Li YL, Zhou LJ, Sun XN, Wang YL, Du LJ, et al. Mineralocorticoid receptor deficiency in Treg cells ameliorates DSS-induced colitis in a gut microbiota-dependent manner. Immunology. (2022) 167:94–104. doi: 10.1111/imm.13522
78. Wang Z, Li B, Bao L, Chen Y, Yang J, Xu F, et al. Fusobacterium nucleatum aggravates intestinal barrier impairment and colitis through IL-8 induced neutrophil chemotaxis by activating epithelial cells. J Inflammation Res. (2024) 17:8407–20. doi: 10.2147/JIR.S470376
79. Oliver AJ, Huang N, Bartolome-Casado R, Li R, Koplev S, Nilsen HR, et al. Single-cell integration reveals metaplasia in inflammatory gut diseases. Nature. (2024) 635:699–707. doi: 10.1038/s41586-024-07571-1
80. Zucoloto AZ, Schlechte J, Ignacio A, Thomson CA, Pyke S, Yu IL, et al. Vascular traffic control of neutrophil recruitment to the liver by microbiota-endothelium crosstalk. Cell Rep. (2023) 42:112507. doi: 10.1016/j.celrep.2023.112507
81. Ren X, Manzanares LD, Piccolo EB, Urbanczyk JM, Sullivan DP, Yalom LK, et al. Macrophage-endothelial cell crosstalk orchestrates neutrophil recruitment in inflamed mucosa. J Clin Invest. (2023) 133:e170733. doi: 10.1172/JCI170733
82. Holani R, Babbar A, Blyth GAD, Lopes F, Jijon H, McKay DM, et al. Cathelicidin-mediated lipopolysaccharide signaling via intracellular TLR4 in colonic epithelial cells evokes CXCL8 production. Gut Microbes. (2020) 12:1785802. doi: 10.1080/19490976.2020.1785802
83. Larsen JM. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology. (2017) 151:363–74. doi: 10.1111/imm.12760
84. Chen Z, Luo J, Li J, Kim G, Stewart A, Huang Y, et al. Intestinal IL-33 promotes platelet activity for neutrophil recruitment during acute inflammation. Blood. (2022) 139:1878–91. doi: 10.1182/blood.2021013474
85. Opdenakker G, Vermeire S, and Abu El-Asrar A. How to place the duality of specific MMP-9 inhibition for treatment of inflammatory bowel diseases into clinical opportunities? Front Immunol. (2022) 13:983964. doi: 10.3389/fimmu.2022.983964
86. Zhang L, Zheng B, Bai Y, Zhou J, Zhang XH, Yang YQ, et al. Exosomes-transferred LINC00668 contributes to thrombosis by promoting NETs formation in inflammatory bowel disease. Adv Sci (Weinh). (2023) 10:e2300560. doi: 10.1002/advs.202300560
87. Chu C, Wang X, Chen F, Yang C, Shi L, Xu W, et al. Neutrophil extracellular traps aggravate intestinal epithelial necroptosis in ischaemia-reperfusion by regulating TLR4/RIPK3/FUNDC1-required mitophagy. Cell Prolif. (2024) 57:e13538. doi: 10.1111/cpr.13538
88. Lin Y, Cai Q, Luo Y, Li B, Chen Y, Yang X, et al. Epithelial chemerin-CMKLR1 signaling restricts microbiota-driven colonic neutrophilia and tumorigenesis by up-regulating lactoperoxidase. Proc Natl Acad Sci U.S.A. (2022) 119:e2205574119. doi: 10.1073/pnas.2205574119
89. Suchitha GP, Devasahayam Arokia Balaya R, Prasad TSK, and Dagamajalu S. A signaling network map of Lipoxin (LXA4): an anti-inflammatory molecule. Inflammation Res. (2024) 73:1099–106. doi: 10.1007/s00011-024-01885-6
90. Levy BD, Clish CB, Schmidt B, Gronert K, and Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. (2001) 2:612–9. doi: 10.1038/89759
91. Maderna P and Godson C. Lipoxins: resolutionary road. Br J Pharmacol. (2009) 158:947–59. doi: 10.1111/j.1476-5381.2009.00386.x
92. Wang S, Song Y, Wang Z, Chang X, Wu H, Yan Z, et al. Neutrophil-derived PAD4 induces citrullination of CKMT1 exacerbates mucosal inflammation in inflammatory bowel disease. Cell Mol Immunol. (2024) 21:620–33. doi: 10.1038/s41423-024-01158-6
93. Salem M, El Azreq MA, Pelletier J, Robaye B, Aoudjit F, and Sévigny J. Exacerbated intestinal inflammation in P2Y6 deficient mice is associated with Th17 activation. Biochim Biophys Acta Mol Bas Dis. (2019) 1865:2595–605. doi: 10.1016/j.bbadis.2019.06.019
94. Wang F, Zhou F, Peng J, Chen H, Xie J, Liu C, et al. Macrophage Tim-3 maintains intestinal homeostasis in DSS-induced colitis by suppressing neutrophil necroptosis. Redox Biol. (2024) 70:103072. doi: 10.1016/j.redox.2024.103072
95. Ginhoux F and Guilliams M. Tissue-resident macrophage ontogeny and homeostasis. Immunity. (2016) 44:439–49. doi: 10.1016/j.immuni.2016.02.024
96. Mohammadnezhad L, Shekarkar Azgomi M, La Manna MP, Sireci G, Rizzo C, Badami GD, et al. Metabolic reprogramming of innate immune cells as a possible source of new therapeutic approaches in autoimmunity. Cells. (2022) 11:1663. doi: 10.3390/cells11101663
97. Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. (2022) 40:509–523.e6. doi: 10.1016/j.ccell.2022.04.004
98. Miossec P and Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. (2012) 11:763–76. doi: 10.1038/nrd3794
99. Wu Y, Ma J, Yang X, Nan F, Zhang T, Ji S, et al. Neutrophil profiling illuminates anti-tumor antigen-presenting potency. Cell. (2024) 187:1422–1439.e24. doi: 10.1016/j.cell.2024.02.005
100. Vono M, Lin A, Norrby-Teglund A, Koup RA, Liang F, and Loré K. Neutrophils acquire the capacity for antigen presentation to memory CD4+ T cells in vitro and ex vivo. Blood. (2017) 129:1991–2001. doi: 10.1182/blood-2016-10-744441
101. Tiberti S, Catozzi C, Croci O, Ballerini M, Cagnina D, Soriani C, et al. GZMKhigh CD8+ T effector memory cells are associated with CD15high neutrophil abundance in non-metastatic colorectal tumors and predict poor clinical outcome. Nat Commun. (2022) 13:6752. doi: 10.1038/s41467-022-34467-3
102. Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, and Sautès-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol. (2022) 19:441–57. doi: 10.1038/s41571-022-00619-z
103. Yue B, Gao R, Lv C, Yu Z, Wang H, Geng X, et al. Berberine improves irinotecan-induced intestinal mucositis without impairing the anti-colorectal cancer efficacy of irinotecan by inhibiting bacterial β-glucuronidase. Front Pharmacol. (2021) 12:774560. doi: 10.3389/fphar.2021.774560
104. Tang W, Ma J, Chen K, Wang K, Chen Z, Chen C, et al. Berbamine ameliorates DSS-induced colitis by inhibiting peptidyl-arginine deiminase 4-dependent neutrophil extracellular traps formation. Eur J Pharmacol. (2024) 975:176634. doi: 10.1016/j.ejphar.2024.176634
105. Bastaki SMA, Amir N, Adeghate E, and Ojha S. Lycopodium mitigates oxidative stress and inflammation in the colonic mucosa of acetic acid-induced colitis in rats. Molecules. (2022) 27:2774. doi: 10.3390/molecules27092774
106. Zhang JX, Dang SC, Qu JG, and Wang XQ. Preventive effect of tetramethylpyrazine on intestinal mucosal injury in rats with acute necrotizing pancreatitis. World J Gastroenterol. (2006) 12:6386–90. doi: 10.3748/wjg.v12.i39.6386
107. Zhang L, Liu H, Zhang H, Yuan H, and Ren D. Lemairamin (Wgx-50) attenuates DSS-induced intestinal inflammation in zebrafish. Int J Mol Sci. (2024) 25:9510. doi: 10.3390/ijms25179510
108. Niu X, Zhang H, Li W, Wang Y, Mu Q, Wang X, et al. Protective effect of cavidine on acetic acid-induced murine colitis via regulating antioxidant, cytokine profile and NF-κB signal transduction pathways. Chem Biol Interact. (2015) 239:34–45. doi: 10.1016/j.cbi.2015.06.026
109. Liu L, Gao H, Wen T, Gu T, Zhang S, and Yuan Z. Tanshinone IIA attenuates AOM/DSS-induced colorectal tumorigenesis in mice via inhibition of intestinal inflammation. Pharm Biol. (2021) 59:89–96. doi: 10.1080/13880209.2020.1865412
110. Ge H, Tang H, Liang Y, Wu J, Yang Q, Zeng L, et al. Rhein attenuates inflammation through inhibition of NF-κB and NALP3 inflammasome in vivo and in vitro. Drug Des Devel Ther. (2017) 11:1663–71. doi: 10.2147/DDDT.S133069
111. Kai L, Zong X, Jiang Q, Lu Z, Wang F, Wang Y, et al. Protective effects of polysaccharides from Atractylodes macrocephalae Koidz. against dextran sulfate sodium induced intestinal mucosal injury on mice. Int J Biol Macromol. (2022) 195:142–51. doi: 10.1016/j.ijbiomac.2021.12.042
112. Zhao M, Tang F, Huang X, Ma J, Wang F, and Zhang P. Polysaccharide Isolated from Agaricus blazei Murill Alleviates Intestinal Ischemia/Reperfusion Injury through Regulating Gut Microbiota and Mitigating Inflammation in Mice. J Agric Food Chem. (2024) 72:2202–13. doi: 10.1021/acs.jafc.3c08482
113. Liu X, Chen S, Liu H, Xie J, Hasan KMF, Zeng Q, et al. Structural properties and anti-inflammatory activity of purified polysaccharides from Hen-of-the-woods mushrooms (Grifola frondosa). Front Nutr. (2023) 10:1078868. doi: 10.3389/fnut.2023.1078868
114. Wang Z, Yan W, Lin X, Qin G, Li K, Jiang L, et al. Forsythiaside A alleviates ulcerative colitis and inhibits neutrophil extracellular traps formation in the mice. Phytother Res. (2025) 39:2165–79. doi: 10.1002/ptr.8440
115. Tang S, Zhong W, Li T, Li Y, and Song G. Isochlorogenic acid A alleviates dextran sulfate sodium-induced ulcerative colitis in mice through STAT3/NF-кB pathway. Int Immunopharmacol. (2023) 118:109989. doi: 10.1016/j.intimp.2023.109989
116. Zhang Z, Wu X, Cao S, Cromie M, Shen Y, Feng Y, et al. Chlorogenic acid ameliorates experimental colitis by promoting growth of akkermansia in mice. Nutrients. (2017) 9:677. doi: 10.3390/nu9070677
117. Liao Q, Zhou X, Wu L, Yang Y, Zhu X, Liao H, et al. Gut microbial metabolite 4-hydroxybenzeneacetic acid drives colorectal cancer progression via accumulation of immunosuppressive PMN-MDSCs. J Clin Invest. (2025) 135:e181243. doi: 10.1172/JCI181243
118. Kadri CJ, Pereira JA, Campos FG, Ortega MM, Bragion CB, and Martinez CA. Anti-inflammatory effects of enemas containing an oily extract of curcumin in an experimental model of diversion colitis. Histol Histopathol. (2017) 32:161–9. doi: 10.14670/HH-11-783
119. Mouzaoui S, Rahim I, and Djerdjouri B. Aminoguanidine and curcumin attenuated tumor necrosis factor (TNF)-α-induced oxidative stress, colitis and hepatotoxicity in mice. Int Immunopharmacol. (2012) 12:302–11. doi: 10.1016/j.intimp.2011.10.010
120. Wei SY, Wu TT, Huang JQ, Kang ZP, Wang MX, Zhong YB, et al. Curcumin alleviates experimental colitis via a potential mechanism involving memory B cells and Bcl-6-Syk-BLNK signaling. World J Gastroenterol. (2022) 28:5865–80. doi: 10.3748/wjg.v28.i40.5865
121. Peng L, Gao X, Nie L, Xie J, Dai T, Shi C, et al. Astragalin attenuates dextran sulfate sodium (DSS)-induced acute experimental colitis by alleviating gut microbiota dysbiosis and inhibiting NF-κB activation in mice. Front Immunol. (2020) 11:2058. doi: 10.3389/fimmu.2020.02058
122. Chen F, Chu C, Wang X, Yang C, Deng Y, Duan Z, et al. Hesperetin attenuates sepsis-induced intestinal barrier injury by regulating neutrophil extracellular trap formation via the ROS/autophagy signaling pathway. Food Funct. (2023) 14:4213–27. doi: 10.1039/d2fo02707k
123. Wei Q, Jiang H, Zeng J, Xu J, Zhang H, Xiao E, et al. Quercetin protected the gut barrier in ulcerative colitis by activating aryl hydrocarbon receptor. Phytomedicine. (2025) 140:156633. doi: 10.1016/j.phymed.2025.156633
124. Riemschneider S, Hoffmann M, Slanina U, Weber K, Hauschildt S, and Lehmann J. Indol-3-carbinol and quercetin ameliorate chronic DSS-induced colitis in C57BL/6 mice by ahR-mediated anti-inflammatory mechanisms. Int J Environ Res Public Health. (2021) 18:2262. doi: 10.3390/ijerph18052262
125. Li Y, Wu J, Jiang S, and Wang N. Exploring the immunological mechanism of Houttuynia cordata in the treatment of colorectal cancer through combined network pharmacology and experimental validation. Naunyn Schmiedebergs Arch Pharmacol. (2024) 397:9095–110. doi: 10.1007/s00210-024-03203-7
126. Ma X, Li M, Wang X, Xu H, Jiang L, Wu F, et al. Dihydromyricetin ameliorates experimental ulcerative colitis by inhibiting neutrophil extracellular traps formation via the HIF-1α/VEGFA signaling pathway. Int Immunopharmacol. (2024) 138:112572. doi: 10.1016/j.intimp.2024.112572
127. Pan Y, Deng B, Wang T, Zhou Z, Wang J, Gao C, et al. Kurarinone ameliorates intestinal mucosal inflammation via regulating T cell immunity. Front Immunol. (2025) 16:1587479. doi: 10.3389/fimmu.2025.1587479
128. Muià C, Mazzon E, Di Paola R, Genovese T, Menegazzi M, Caputi AP, et al. Green tea polyphenol extract attenuates ischemia/reperfusion injury of the gut. Naunyn Schmiedebergs Arch Pharmacol. (2005) 371:364–74. doi: 10.1007/s00210-005-1076-0
129. Zhang Z, Zhu Q, Wang S, and Shi C. Epigallocatechin-3-gallate inhibits the formation of neutrophil extracellular traps and suppresses the migration and invasion of colon cancer cells by regulating STAT3/CXCL8 pathway. Mol Cell Biochem. (2023) 478:887–98. doi: 10.1007/s11010-022-04550-w
130. Li R, Chi H, Liao X, Cen S, and Zou Y. The glabridin from huangqin decoction prevents the development of ulcerative colitis into colitis-associated colorectal cancer by modulating MMP1/MMP3 activity. Int Immunopharmacol. (2024) 135:112262. doi: 10.1016/j.intimp.2024.112262
131. Bian Y, Lei J, Zhong J, Wang B, Wan Y, Li J, et al. Kaempferol reduces obesity, prevents intestinal inflammation, and modulates gut microbiota in high-fat diet mice. J Nutr Biochem. (2022) 99:108840. doi: 10.1016/j.jnutbio.2021.108840
132. Sheng Q, Li F, Chen G, Li J, Li J, Wang Y, et al. Ursolic acid regulates intestinal microbiota and inflammatory cell infiltration to prevent ulcerative colitis. J Immunol Res. (2021) 2021:6679316. doi: 10.1155/2021/6679316
133. Chen YL, Xu B, Pan ZF, Cai YP, Yang CY, Cao SL, et al. Glycyrrhizic acid reduces neutrophil extracellular trap formation to ameliorate colitis-associated colorectal cancer by inhibiting peptidylarginine deiminase 4. J Ethnopharmacol. (2025) 341:119337. doi: 10.1016/j.jep.2025.119337
134. Zhang Y, Zha Z, Shen W, Li D, Kang N, Chen Z, et al. Anemoside B4 ameliorates TNBS-induced colitis through S100A9/MAPK/NF-κB signaling pathway. Chin Med. (2021) 16:11. doi: 10.1186/s13020-020-00410-1
135. Bastaki SM, Adeghate E, Amir N, Ojha S, and Oz M. Menthol inhibits oxidative stress and inflammation in acetic acid-induced colitis in rat colonic mucosa. Am J Transl Res. (2018) 10:4210–22. Available online at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6325525/.
136. Liu C, He YX, Zhang JN, Yang F, Wang SY, Hu JL, et al. Angelica oil restores the intestinal barrier function by suppressing S100A8/A9 signalling in mice with ulcerative colitis. Phytomedicine. (2023) 108:154490. doi: 10.1016/j.phymed.2022.154490
137. Baker J, Brown K, Rajendiran E, Yip A, DeCoffe D, Dai C, et al. Medicinal lavender modulates the enteric microbiota to protect against Citrobacter rodentium-induced colitis. Am J Physiol GI Liv Physiol. (2012) 303:G825–36. doi: 10.1152/ajpgi.00327.2011
138. Bastaki SMA, Amir N, Adeghate E, and Ojha S. Nerolidol, a sesquiterpene, attenuates oxidative stress and inflammation in acetic acid-induced colitis in rats. Mol Cell Biochem. (2021) 476:3497–512. doi: 10.1007/s11010-021-04094-5
139. Fangxiao M, Yifan K, Jihong Z, Yan S, and Yingchao L. Effect of tripterygium wilfordii polycoride on the NOXs-ROS-NLRP3 inflammasome signaling pathway in mice with ulcerative colitis. Evid Bsd Comp Alt Med. (2019) 2019:9306283. doi: 10.1155/2019/9306283
140. Du K, Foote MS, Mousavi S, Buczkowski A, Schmidt S, Bereswill S, et al. Less pronounced immunopathological responses following oral butyrate treatment of campylobacterjejuni-infected mice. Microorganisms. (2022) 10:1953. doi: 10.3390/microorganisms10101953
141. Li G, Lin J, Zhang C, Gao H, Lu H, Gao X, et al. Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease. Gut Microbes. (2021) 13:1968257. doi: 10.1080/19490976.2021.1968257
142. Hayashi A, Nagao-Kitamoto H, Kitamoto S, Kim CH, and Kamada N. The Butyrate-Producing Bacterium Clostridium butyricum Suppresses Clostridioides difficile Infection via Neutrophil- and Antimicrobial Cytokine-Dependent but GPR43/109a-Independent Mechanisms. J Immunol. (2021) 206:1576–85. doi: 10.4049/jimmunol.2000353
143. Shen S, Prame Kumar K, Wen SW, Shim R, Wanrooy BJ, Stanley D, et al. Deficiency of dietary fiber modulates gut microbiota composition, neutrophil recruitment and worsens experimental colitis. Front Immunol. (2021) 12:619366. doi: 10.3389/fimmu.2021.619366
144. Liao X, Lan Y, Wang W, Zhang J, Shao R, Yin Z, et al. Vitamin D influences gut microbiota and acetate production in zebrafish (Danio rerio) to promote intestinal immunity against invading pathogens. Gut Microbes. (2023) 15:2187575. doi: 10.1080/19490976.2023.2187575
145. Bravo-Tello K, Ehrenfeld N, Solís CJ, Ulloa PE, Hedrera M, Pizarro-Guajardo M, et al. Effect of microalgae on intestinal inflammation triggered by soybean meal and bacterial infection in zebrafish. PloS One. (2017) 12:e0187696. doi: 10.1371/journal.pone.0187696
146. Li L, Huang J, Feng L, Xu L, Lin H, Liu K, et al. Altechromone A ameliorates inflammatory bowel disease by inhibiting NF-κB and NLRP3 pathways. Mar Drugs. (2024) 22:410. doi: 10.3390/md22090410
147. Feng YL, Xu XR, Zhu QM, Chang J, Zhang HL, Wang N, et al. Aucklandiae radix targeted PKM2 to alleviate ulcerative colitis: Insights from the photocrosslinking target fishing technique. Phytomedicine. (2024) 134:155973. doi: 10.1016/j.phymed.2024.155973
148. Kruk A, Granica S, Popowski D, Malinowska N, and Piwowarski JP. Tiliae flos metabolites and their beneficial influence on human gut microbiota biodiversity ex vivo. J Ethnopharmacol. (2022) 294:115355. doi: 10.1016/j.jep.2022.115355
149. Tendean M and Riwanto I. The effects of phyllanthus niruri linn on infiltrating dendritic cell and ratio of neutrophile/lymphocytes in chemotherapy of sprague-dawley rats with colorectal cancer. Asian Pac J Cancer Prev. (2021) 22:3561–8. doi: 10.31557/APJCP.2021.22.11.3561
150. Kim M, Chung KS, Hwang SJ, Yoon YS, Jang YP, Lee JK, et al. (Chickpea) ethanol extract in the dextran sulfate sodium-induced mouse model of ulcerative colitis. Nutrients. (2020) 12:456. doi: 10.3390/nu12020456
151. Pan P, Skaer C W, Wang HT, Oshima K, Huang YW, Yu J, et al. Loss of free fatty acid receptor 2 enhances colonic adenoma development and reduces the chemopreventive effects of black raspberries in ApcMin/+ mice. Carcinogenesis. (2017) 38:86–93. doi: 10.1093/carcin/bgw122
152. Lee A, Chung YC, Kim KY, Jang CH, Song KH, and Hwang YH. Hydroethanolic extract of fritillariae thunbergii bulbus alleviates dextran sulfate sodium-induced ulcerative colitis by enhancing intestinal barrier integrity. Nutrients. (2023) 15:2810. doi: 10.3390/nu15122810
153. Li Y, Tian YY, Wang J, Lin R, Zhang Y, Zhang MM, et al. Main active components of Ilex rotunda Thunb. protect against ulcerative colitis by restoring the intestinal mucosal barrier and modulating the cytokine-cytokine interaction pathways. J Ethnopharmacol. (2024) 318:116961. doi: 10.1016/j.jep.2023.116961
154. Cury BJ, Jerônimo DT, da Silva LM, Farias De Queiroz E Silva T, França TCS, Santos AC, et al. Hydroalcoholic extract of Araucaria sp. brown propolis alleviates ulcerative colitis induced by TNBS in rats by reducing inflammatory cell infiltration and oxidative damage. J Pharm Pharmacol. (2024) 76:1379–92. doi: 10.1093/jpp/rgae083
155. Fokam Tagne MA, Kom B, Foyet Fondjo A, Noubissi PA, Talom Tangue B, Gaffo EF, et al. Evaluation of anticolitis and antioxidant properties of bixa orellana (Bixaceae) leaf hydroethanolic extract on acetic acid-induced ulcerative colitis in rats. Curr Ther Res Clin Exp. (2022) 97:100685. doi: 10.1016/j.curtheres.2022.100685
156. Hoffmann M, Schwertassek U, Seydel A, Weber K, Hauschildt S, and Lehmann J. Therapeutic efficacy of a combined sage and bitter apple phytopharmaceutical in chronic DSS-induced colitis. Sci Rep. (2017) 7:14214. doi: 10.1038/s41598-017-13985-x
157. Wu F, Shao Q, Cheng Z, Xiong X, Fang K, Zhao Y, et al. Traditional herbal formula Wu-Mei-Wan alleviates TNBS-induced colitis in mice by inhibiting necroptosis through increasing RIPK3 O-GlcNAcylation. Chin Med. (2021) 16:78. doi: 10.1186/s13020-021-00493-4
158. Pan Z, Xie X, Chen Y, Pan S, Wu Z, Yang C, et al. Huang Qin Decoction inhibits the initiation of experimental colitis associated carcinogenesis by controlling the PAD4 dependent NETs. Phytomedicine. (2022) 107:154454. doi: 10.1016/j.phymed.2022.154454
159. Zhao H, Sun L, Xiao X, Lin J, Shao C, and Lin L. Qu-yu-jie-du decoction ameliorates dextran sulfate sodium-induced colitis in mice by modulation of neutrophils and macrophage infiltration. Evid Bsd Comp Alt Med. (2022) 2022:3762591. doi: 10.1155/2022/3762591
160. Li YY, He YX, Wu YQ, Liu C, Ren LZ, Lu XY, et al. Compatibility between cold-natured medicine CP and hot-natured medicine AZ synergistically mitigates colitis mice through attenuating inflammation and restoring gut barrier. J Ethnopharmacol. (2023) 303:115902. doi: 10.1016/j.jep.2022.115902
161. Lin MK, Yang YT, Lin LJ, Yu WH, and Chen HY. Pulsatilla decoction suppresses matrix metalloproteinase-7-mediated leukocyte recruitment in dextran sulfate sodium-induced colitis mouse model. BMC Comp Med Ther. (2022) 22:211. doi: 10.1186/s12906-022-03696-w
162. Wang Y, Wu H, Sun J, Li C, Fang Y, Shi G, et al. Effects of the N-butanol extract of pulsatilla decoction on neutrophils in a mouse model of ulcerative colitis. Pharm (Basel). (2024) 17:1077. doi: 10.3390/ph17081077
163. Zhang D, Duan S, He Z, Zhu Z, Li Z, Yi Q, et al. Sijunzi decoction targets IL1B and TNF to reduce neutrophil extracellular traps (NETs) in ulcerative colitis: evidence from silicon prediction and experiment validation. Drug Des Devel Ther. (2023) 17:3103–28. doi: 10.2147/DDDT.S428814
164. Cicero AF and Baggioni A. Berberine and its role in chronic disease. Adv Exp Med Biol. (2016) 928:27–45. doi: 10.1007/978-3-319-41334-1_2
165. Neubert E, Meyer D, Rocca F, Günay G, Kwaczala-Tessmann A, Grandke J, et al. Chromatin swelling drives neutrophil extracellular trap release. Nat Commun. (2018) 9:3767. doi: 10.1038/s41467-018-06263-5
166. Krawisz JE, Sharon P, and Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. (1984) 87:1344–50. doi: 10.1016/0016-5085(84)90202-6
167. Zhang X, Tian X, Wang Y, Yan Y, Wang Y, Su M, et al. Application of lipopolysaccharide in establishing inflammatory models. Int J Biol Macromol. (2024) 279:135371. doi: 10.1016/j.ijbiomac.2024.135371
168. Shin HS, Satsu H, Bae MJ, Zhao Z, Ogiwara H, Totsuka M, et al. Anti-inflammatory effect of chlorogenic acid on the IL-8 production in Caco-2 cells and the dextran sulphate sodium-induced colitis symptoms in C57BL/6 mice. Food Chem. (2015) 168:167–75. doi: 10.1016/j.foodchem.2014.06.100
169. Kang CS, Ban M, Choi EJ, Moon HG, Jeon JS, Kim DK, et al. Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis. PloS One. (2013) 8:e76520. doi: 10.1371/journal.pone.0076520
170. Anderson SM, Tomayko MM, Ahuja A, Haberman AM, and Shlomchik MJ. New markers for murine memory B cells that define mutated and unmutated subsets. J Exp Med. (2007) 204:2103–14. doi: 10.1084/jem.20062571
171. Riaz A, Rasul A, Hussain G, Zahoor MK, Jabeen F, Subhani Z, et al. Astragalin: A bioactive phytochemical with potential therapeutic activities. Adv Pharmacol Sci. (2018) 2018:9794625. doi: 10.1155/2018/9794625
172. Jäger S, Trojan H, Kopp T, Laszczyk MN, and Scheffler A. Pentacyclic triterpene distribution in various plants-rich sources for a new group of multi-potent plant extracts. Molecules. (2009) 14:2016–31. doi: 10.3390/molecules14062016
173. Leshchenko EV, Berdyshev DV, Yurchenko EA, Antonov AS, Borkunov GV, Kirichuk NN, et al. Bioactive Polyketides from the Natural Complex of the Sea Urchin-Associated Fungi Penicillium sajarovii KMM 4718 and Aspergillus protuberus KMM 4747. Int J Mol Sci. (2023) 24:16568. doi: 10.3390/ijms242316568
174. Yuan S and Hu Q. Convergence of nanomedicine and neutrophils for drug delivery. Bioact Mater. (2024) 35:150–66. doi: 10.1016/j.bioactmat.2024.01.022
175. Liu Y, Yu Y, Wang M, Zhang C, and Li C. Recent progress in therapeutic strategies and biomimetic nanomedicines based on neutrophils for inflammation treatment. Nanomed (Lond). (2023) 18:485–500. doi: 10.2217/nnm-2022-0211
176. Zhao Y, Zhang H, Zhang Q, and Tao H. Research progress of neutrophil-mediated drug delivery strategies for inflammation-related disease. Pharmaceutics. (2023) 15:1881. doi: 10.3390/pharmaceutics15071881
177. Kalluri R. The biology and function of extracellular vesicles in immune response and immunity. Immunity. (2024) 57:1752–68. doi: 10.1016/j.immuni.2024.07.009
178. Yang Y, Yang L, Deng H, Liu Y, Wu J, Yang Y, et al. Coptis chinensis-derived extracellular vesicle-like nanoparticles delivered miRNA-5106 suppresses NETs by restoring zinc homeostasis to alleviate colitis. J Nanobiotech. (2025) 23:444. doi: 10.1186/s12951-025-03466-z
179. Yang Y, Yang L, Yang Y, Deng H, Su S, Xia Y, et al. Bacteroides fragilis-derived outer membrane vesicles deliver miR-5119 and alleviate colitis by targeting PD-L1 to inhibit GSDMD-mediated neutrophil extracellular trap formation. Adv Sci (Weinh). (2025) 12:e00781. doi: 10.1002/advs.202500781
180. Zhang YL, Wang YL, Yan K, Li H, Zhang X, Essola JM, et al. Traditional chinese medicine formulae QY305 reducing cutaneous adverse reaction and diarrhea by its nanostructure. Adv Sci (Weinh). (2024) 11:e2306140. doi: 10.1002/advs.202306140
181. Huang L, Huang XH, Yang X, Hu JQ, Zhu YZ, Yan PY, et al. Novel nano-drug delivery system for natural products and their application. Pharmacol Res. (2024) 201:107100. doi: 10.1016/j.phrs.2024.107100
182. Wu J, Wang L, Lu H, Huo Y, Guo Z, Cheng Y, et al. Inulin hydrogel loaded with self-assembled nanoparticles of curcumin and glycyrrhizic acid for inflammatory bowel disease treatment via anti-inflammation, antioxidation, and microbiota modulation. Mol Pharm. (2025) 22:5410–27. doi: 10.1021/acs.molpharmaceut.5c00383
183. Wang CJ, Ko GR, Lee YY, Park J, Park W, Park TE, et al. Polymeric DNase-I nanozymes targeting neutrophil extracellular traps for the treatment of bowel inflammation. Nano Converg. (2024) 11:6. doi: 10.1186/s40580-024-00414-9
184. Dong W, Liu D, Zhang T, You Q, Huang F, and Wu J. Oral delivery of staphylococcal nuclease ameliorates DSS induced ulcerative colitis in mice via degrading intestinal neutrophil extracellular traps. Ecotoxicol Environ Saf. (2021) 215:112161. doi: 10.1016/j.ecoenv.2021.112161
185. Chang Y, Cai X, Syahirah R, Yao Y, Xu Y, Jin G, et al. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy. Nat Commun. (2023) 14:2266. doi: 10.1038/s41467-023-37872-4
186. Wang J, Deng T, Chen R, Yang L, Teng Y, and Miao J. Engineered neutrophil, an emerging immune therapeutic strategy. Inn Immun. (2025) 31:17534259251365803. doi: 10.1177/17534259251365803
187. Kolaczkowska E and Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. (2013) 13:159–75. doi: 10.1038/nri3399
188. Chang Y, Hummel SN, Watson MN, Jin G, Lian XL, and Bao X. Engineered artificial human neutrophils exhibit mature functional performance. ACS Synth Biol. (2023) 12:2262–70. doi: 10.1021/acssynbio.3c00309
189. Gao L, Liu Y, Ye L, Liang S, Lin J, Zeng J, et al. Metal ion coordinated tea polyphenol nanocoating for enhanced probiotic therapy in inflammatory bowel disease. Biomaterials. (2025) 321:123323. doi: 10.1016/j.biomaterials.2025.123323
190. Sharma S, Masud MK, Kaneti YV, Rewatkar P, Koradia A, Hossain MSA, et al. Extracellular vesicle nanoarchitectonics for novel drug delivery applications. Small. (2021) 17:e2102220. doi: 10.1002/smll.202102220
191. Liang W, Zhang W, Tian J, Zhang X, Lv X, Qu A, et al. Advances in carbohydrate-based nanoparticles for targeted therapy of inflammatory bowel diseases: A review. Int J Biol Macromol. (2024) 281:136392. doi: 10.1016/j.ijbiomac.2024.136392
192. Li X, Zhu R, Liu Q, Sun H, Sheng H, and Zhu L. Effects of traditional Chinese medicine polysaccharides on chronic diseases by modulating gut microbiota: A review. Int J Biol Macromol. (2024) 282:136691. doi: 10.1016/j.ijbiomac.2024.136691
Keywords: cell interactions, intestinal immune diseases, intestinal neutrophils, natural products, novel therapeutic techniques
Citation: Kang R, Sun A, Yang J, Chang L, Sun W, Kou F and Cheng Y (2026) Targeting the plasticity of intestinal neutrophils: bidirectional regulation strategies by natural products. Front. Immunol. 16:1754107. doi: 10.3389/fimmu.2025.1754107
Received: 25 November 2025; Accepted: 19 December 2025; Revised: 16 December 2025;
Published: 12 January 2026.
Edited by:
Haiqiang Yao, Beijing University of Chinese Medicine, ChinaReviewed by:
Xingwei Ding, Nanchang University, ChinaHideyuki Masui, Hirakata Kousai Hospital, Japan
Copyright © 2026 Kang, Sun, Yang, Chang, Sun, Kou and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yuan Cheng, MjkwNTM1QG5qdWNtLmVkdS5jbg==; Fushun Kou, a291ZnVzaHVuQDEyNi5jb20=
†These authors have contributed equally to this work